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Abstract
Treatments, when customized according to individual patient attributes, are in recent years
referred to as personalized medicines. Personalized medicines aim at improving the ther-
apeutic outcome of the patient. However, current pharmaceutical production is dominated
by mass production in a batch manner, i.e. producing large volumes of identical products.
Uncertainties prevail regarding the ability of current production to respond to the prod-
uct customization need in an economically and technically realizable manner. However,
without customized treatment reaching the patient the benefit of personalized medicines
cannot be achieved. Hence, a mass customization-paradigm, i.e. economic feasibility
when designing, producing and delivering customized pharmaceutical products, is de-
sired.
Pharmaceutical product customization has been discussed from a product and produc-
tion perspective. These discussions mainly focus either on product or production de-
sign. Additionally, the economic feasibility of suggested approaches is not fully explored.
Mass customization requires joint consideration of product and production system design.
Hence, the aim of this thesis is to explore integrated pharmaceutical product and produc-
tion system design facilitating a shift toward mass customization-paradigm.
Methodologies to design the integrated product and production systems of pharmaceu-
tical products supporting customization are proposed. Set-based concurrent engineer-
ing (SBCE) principles are adapted due to the ability of efficient product development.
Platform-based design is adapted due to a successful approach to mass customization in
manufacturing industry. Additionally, an integrated design approach to product value as-
sessment is proposed to emphasize the customized pharmaceutical product value.
The methodology application is illustrated for oral dosage forms for the purpose of demon-
strating refined approaches to integrated design of these. Knowledge regarding oral dosage
forms as enablers for personalized medicines is generated.
Results show that the adaption of SBCE principles enables efficient consequence analysis
of pharmaceutical product designs for production system designs and is accomplished by
acquiring a set-based approach to simultaneous assessment of the performance of various
designs. Platform-based design enables flexible pharmaceutical product and production
system design, thus supporting mass customization. Finally, oral dosage forms embracing
modularized designs provide substantial product design flexibility but affects manufactur-
ing complexity and hence, the discussion of product and production system design cannot
be separated.
Keywords: Personalized medicines, Mass customization, Integrated product and produc-
tion platforms
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CHAPTER 1
Introduction
The aimed value of personalized medicines is to enhance the therapeutic outcome of the
patient, i.e. ensuring a safe and effective treatment [Ahmed et al. 2016, Meyer, 2004].
Personalized medicine can refer to the means to map the characteristics of a patient in
order to guide therapeutic decisions of the patient. Another usage of the term person-
alized medicines refers to the means to provide treatment, i.e. the dosage form, tablet,
capsule, inhaler and so forth, that is tailored according to individual attributes to optimize
the treatment of the patient [Crommelin et al. 2011]. The former concept personalized
medicine has made significant progress due to advances in diagnostics, nanotechnology
and so forth, but the latter concept personalized medicines, i.e. tailoring the treatment
according to patient attributes, remains at a more infant stage due to the lack of suffi-
cient tools of developing tailored treatments, that can be designed according to patient
characteristics, but also manufactured and distributed to an economically feasible man-
ner [Gaspar et al. 2012]. To gain the full benefit of personalized medicines, these two
concepts need to be connected when the maturity of each concept reaches a sufficient
level. The therapeutic outcome of the patient cannot be improved if there are no cus-
tomized treatments to enable this. Mass customization can be defined in the context of
pharmaceutical products as designing, manufacturing and supplying customized products
in an economically feasible manner [Govender, 2019]. Hence, the effort of this thesis is
to advance the concept of personalized medicines focusing on the product and produc-
tion design to enable treatment customization in an economically feasible manner, thus,
into approaches contributing to a mass customization-paradigm of pharmaceutical prod-
ucts. The formulated drug product is intended throughout this thesis, when discussing
pharmaceutical product design.
1.1 Background
Variable patient response to drugs has been a documented fact over the past six decades.
Emerging research has shown that patient variability to drug response can be attributed
to various biologically determined factors, but also to environmentally and behaviorally
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determined factors [Vogenberg et al. 2010]. The understanding of underlying causes of
various diseases started improving during the 19th century because of adequate advances
in the scientific fields of chemistry, microscopy and so forth. Halfway through the 20th
century, drug response could be mapped to individual metabolic characteristics. Finally,
in the 21st century, the sequencing of human genomics emerged and hence the term per-
sonalized medicine was coined [U.S. Food and Drug Administration, 2013].
1.1.1 Problem analysis
Regardless of advancements in patient diagnostics, sequencing of human genomics and
so forth, most pharmaceutical products still remain in the one-size-fits-all-paradigm. The
one-size-fits-all-paradigm implies offering each patient the same type of medication to the
same symptoms regardless of inter-patient variability.
On one hand, the current lack of tools predicting the patient response to treatments for
most diseases gives doctors no choice rather than following the trial-and-error approach
when prescribing a type of medication. In the event of unsatisfactory therapeutic effect,
the medication is changed [U.S. Food and Drug Administration, 2013]. In addition, the
existing production platforms are constraining the number of different product variants
that are required to satisfy the therapeutic need of each stratified patient group [Wilson,
2016]. Pharmaceutical manufacturing is still governed by mass production in a batch
manner with low flexibility and hence uncertainties lies in the level of customization that
can be obtained with these platforms. Albeit, continuous production approaches are in-
crementally adopted by the pharmaceutical industry [Lee et al. 2015, Plumb, 2005].
A reason for batch-processing being the dominant approach to pharmaceutical pro-
duction originates, at least partly, from the highly regulated production environment of
pharmaceutical products. The time from drug discovery to market launch consumes a
vast portion of patent time. Hence, the time of producing and selling the product on the
market before exposed to low-cost competition is short. Additionally, making changes
into the production processes of a filed product is a elaborate and complex process with
respect to process validation and approvance, and simply, making changes to the pro-
duction platforms of pharmaceutical products is not perceived as an economically sound
business case [Suresh and Basu, 2008].
In response to breakthroughs in diagnostics, sequencing of human genomics and so
forth, research regarding pharmaceutical product customization has been emerging. From
a product design perspective, discussions of enablers for customization regard multiple
unit dosage forms, such as modularized product designs, pellet-based dosage forms or
mini-tablets, and have touched upon the topic of these dosage forms as being enablers
for mass customization, directly or indirectly [Bonhoeffer et al. 2018, Aleksovski et al.
2015,Tissen et al. 2011,Yeleken et al. 2017]. However, literature verifying the full bene-
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fits of these product designs cannot be found.
Furthermore, research has been focusing on experimenting with novel technologies
of pharmaceutical product design. One such technology is additive manufacturing. By
digital design, the material can be arranged as desired and by a layer-by-layer technique
the product can be printed [Norman et al. 2017]. This provides customization on an in-
dividual level when functionalities of the product can be built to match individual patient
attributes. The economic feasibility of handling the increasing number of product variants
with such a technique currently lacks support. However, from a regulatory perspective,
additive manufacturing might be an option for the future. The US Food and Drug Admin-
istration (FDA) recently approved a 3D-printed medicinal product [U.S. Food and Drug
Administration, 2016].
Besides approaches to customized product design, research considering the manage-
ment of an increasing number of product variants has been emerging. The focus has been
to adjust the existing production platforms and supply chain networks to respond to the
increased need for flexibility caused by an increasing number of product variants. For
example, continuous production and integrated supply chain networks have been widely
researched based on the hypothesis that continuous production provides more robust pro-
cesses and eliminates difficulties regarding scaling the production. By adjusting the run
time of the continuous processes the batch sizes can easily be varied [Plumb, 2005, Srai
et al. 2015].
However, a relevant problem regarding the development of product and production
systems for personalized medicines has been identified. The discussions have either fo-
cused on patient-centric product design, i.e. approaches to product designs enabling an
enhanced therapeutic outcome of the patient such as multiple unit dosage forms, or on
manufacturing technologies enabling a response to an increased number of product vari-
ants such as continuous production technologies. Additive manufacturing is a manufac-
turing technology and a candidate for patient-centric product design, however, the wider
implementation of this technology lacks support. An integrated approach to product and
production design supporting mass customization of pharmaceutical products is lacking.
1.1.2 Product and production development of pharmaceutical
products
Not only is there a need for improvements in product development approaches of person-
alized medicines, but also for pharmaceutical products in general. The current pharmaceu-
tical product development process acquires the nature of a sequential approach generally
based on experimental laboratory work. From the discovery of a new molecular entity, a
series of scale-ups follow to an extent depending on the success of clinical trials [Suresh
and Basu, 2008]. Since the success rate of clinical trials is fairly low, numbers such as
10% success has been reported [Siew, 2017], the focus of pharmaceutical companies is to
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produce pharmaceutical products sufficient, with respect to material amount and quality,
for the clinical trials. Developing long-term, robust production systems have thus been a
secondary focus. The consequence of not putting enough effort into the development of
robust pharmaceutical production processes has been an accumulation of problems during
the commercial production of pharmaceutical products. These problems have inevitably
caused unnecessary costs for pharmaceutical production [Suresh and Basu, 2008].
There is a need, verified by the FDA, for science and engineering-based tools to im-
prove the product development process of pharmaceutical products. The need is for tools
to improve the efficiency of development work by shortening the time from discovery of
a new drug entity to market launch. The tools should enable predictions of product be-
haviour and production system behaviour and hence, provide for robust pharmaceutical
production [U.S. Food and Drug Administration, 2004]. Likewise, tools to predict product
and production system behaviour hence seems a necessity to enable a mass customization-
paradigm of pharmaceutical products as well.
1.1.3 Set-based concurrent engineering
Concurrent engineering is an organizational approach that has attributed many firms,
mainly in the manufacturing industry, with successful results as it has shown effects re-
garding faster market launches of products matching customer needs and expectations
[Wheelwright and Clark, 1992]. Concurrent engineering means cross-functional efforts
in early product development, i.e. the work of various organizational disciplines is con-
ducted in parallel and allows for information flow across these disciplines. Such disci-
plines are product design and production process development [Prasad, 1996]. Set-based
concurrent engineering (SBCE) is an elaboration of concurrent engineering with the same
philosophy of developing products in a cross-disciplinary manner. However, the main
idea for SBCE as a product development philosophy is to work with sets of alternative
solutions and push the decision-making regarding a final solution to a later stage in the
product development process when solutions can systematically with increasing knowl-
edge be narrowed down [Sobek et al. 1999].
1.1.4 Integrated product and production platforms
Platform-based product development is an approach to product development supporting
industries with mass customization considerations. Platforms have been adopted by man-
ufacturing industries, mainly for discrete part production, due to the ability to generate
sets of derivative product variants, i.e. enabling product customization. Platforms have
accomplished satisfying customization needs and are still retaining, on occasions even im-
proving, the business [Wortmann et al. 1996, Ho and Tang, 1998]. Customization is seen
as a strategy to compete on the market by offering product variety and thus, increasing
the perceived benefit of a range of customers. From a company point of view, customiza-
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tion can hence be perceived as a strategy to increase the overall value of the product by
increasing the benefit for a range of customers. In the end, the core purpose of develop-
ing products should be to maximize the perceived value by the customer and improve the
business.
1.2 Aims and goals
Inspired by successful product development approaches adopted in the manufacturing in-
dustry, the overall aim of this thesis is to explore opportunities of adapting integrated prod-
uct and production platform thinking as design methods in the context of pharmaceutical
mass customization. The goal is to find a remedy to the problems of the current tedious,
sequential and experimental development procedure of pharmaceutical products where the
production development is of secondary focus. Further, initial approaches of predictive
tools to develop integrated product and production systems for customized pharmaceuti-
cal products are explored.
This exploration is aiming at addressing the gap of lacking integrated approaches
to pharmaceutical product customization. SBCE principles are adapted in the product
and production development process of pharmaceutical products enabling rapid genera-
tion and assessment of product and production system designs of pharmaceutical prod-
ucts. Further, to facilitate the emerging customization need of pharmaceutical products,
platform-based design approaches are explored to generate pharmaceutical product fam-
ilies supporting a mass customization-paradigm. A support for product customization is
aiming at facilitating an increase in the perceived value by the customer.
Within this thesis, SBCE is seen as a design philosophy supporting the development
work and employed due to the proven efficiency achieved in several businesses [Prasad,
1996]. Since platforms have proven an enabler of feasible product customization [Wort-
mann et al. 1996, Ho and Tang, 1998], a platform-based design approach to product de-
velopment is adapted to support the development of customized pharmaceutical products.
Furthermore, throughout the thesis, several studies are conducted and as an illustrative
example, the modularized tablet design will be used. The purpose of choosing the mod-
ularized tablet design throughout the thesis is to contribute to knowledge regarding the
benefits of modularized tablet designs as enablers for personalized medicines.
The thesis aim is concretized into the following goals:
• To adapt platform-based design approaches in the context of pharmaceutical prod-
uct development to facilitate mass customization of pharmaceutical products
• To propose methodologies by which to develop integrated product and produc-
tion system designs supporting mass customization of pharmaceutical products and
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also, by which to assess these designs
• To adapt SBCE in the context of developing pharmaceutical products to perform
systematic evaluations of sets of design solutions efficiently
• To contribute to the knowledge of the benefits of modularized tablet designs as
enablers for personalized medicines.
The primary context is mass customization of pharmaceutical products. The results
shall be generalizable beyond the context of pharmaceutical product customization.
1.3 Research questions
The aim of this thesis is to explore methods of integrated platform-based design in the
context of personalized medicines governed by SBCE principles. The following research
questions are proposed for this thesis to guide research activities to achieve the research
goals proposed:
RQ1: How can pharmaceutical product designs be established to support product
customization and the consequences of these designs for the production assessed?
The first question aims at studying how pharmaceutical product designs supporting
the customization need can be established in a systematic manner. Moreover, the conse-
quences of these product designs supporting the customization need on pharmaceutical
production are studied.
RQ2: How can the value of pharmaceutical product designs supporting customiza-
tion be assessed?
The second question aims at studying how an assessment of product value can be per-
formed in the context of pharmaceutical products supporting the customization need and
more specifically, how the value of the pharmaceutical product is transformed when the
product design is changed to support customization.
RQ3: How can the product and production system be modeled so that the conse-
quences of changing customer needs can be assessed?
The third question aims to build on the first question but more specifically, to study
the dynamic integration of the product and production system design.
RQ4: How can modularized tablet designs enable personalized medicines?
The fourth question aims at contributing knowledge of modularized tablet designs as
enablers for personalized medicines.
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1.4 Research scope and delimitations
The main context of studies is personalized medicines and hence, each methodology pro-
posed has been developed with personalized medicines in mind. The result of this thesis
is an exploration regarding methodologies to concurrently develop product and produc-
tion system designs and hence, the proposed methodologies will embrace a prescriptive
approach.
The methodologies proposed build highly on platforms. In this thesis, these platforms
are perceived as means to design product and production systems; hence platform-based
design approaches are exercised as the means of developing pharmaceutical products. The
assessment of the platforms as products themselves, i.e. assessing the efficiency of these
platforms to develop product and production systems, is outside the scope of this thesis.
This thesis will propose approaches contributing to a mass customization-paradigm of
pharmaceutical products. This will be performed by suggesting flexible product designs
aiming at supporting mass customization but the connection between patient characteris-
tics and the design parameters of the product will not be studied.
This thesis will focus on oral dosage forms of medicinal products. Furthermore, the
production system considerations are limited to the secondary production of pharmaceuti-
cal products and the consequences of customized product designs on these. Hence, stages
in the product and production development process of pharmaceutical products such as
the discovery of new molecular entities and production of the raw material, including the
active pharmaceutical ingredient (API) and excipients, are outside the scope of this the-
sis. Additionally, considerations regarding regulatory aspects due to the proposal of new
methodologies with which to develop pharmaceutical products are outside the scope of
this thesis.
1.5 Academic and industrial relevance
This thesis should contribute to academic research but it should also have relevance from
an industrial point of view.
The academic purpose of this research is to increase knowledge regarding the product
and production development process of personalized medicines. A methodology of inte-
grated product and production system design in an SBCE manner is facilitating the con-
current product and production system development of pharmaceutical products. Further,
approaches to evaluating these new product and production system designs are proposed.
The methodologies thus support knowledge increase regarding customized product de-
signs and corresponding production systems. Moreover, the application of the methodolo-
gies are illustrated in a modularized tablet design context throughout the thesis to generate
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knowledge regarding the benefits of modularized tablet designs as enablers for personal-
ized medicines.
The industrial purpose is to perform groundwork for a tool to concurrently develop
sets of product and production systems of pharmaceutical products in a predictive manner.
This tool not only supports the work of R&D-engineers at pharmaceutical companies
when new product designs are to be developed but also, facilitates an efficient evaluation
of sets of designs simultaneously and can thus improve the quality output of new product
and production system designs. Finally, this tool will contribute to forming the product
development paradigm of pharmaceutical products from a sequential, laboratory-based
procedure to a predictive modelling and simulation task to improve the quality output of
the product and production systems.
1.6 Outline of the thesis
The thesis is organized as follows; Chapter 1 provides an introduction to the topic and
presents the problem as well as the research questions to be answered. Chapter 2 de-
scribes the frame of reference, the relevant theory and concepts that this thesis is based
upon and critically reviews existing theory and concepts and, consequently, identifies per-
ceived research gaps. Further, approaches to address the perceived research gaps will be
identified. A description regarding the research approach undertaken during the research
work is provided in Chapter 3. Selected results, a collection of highlights from the ap-
pended papers, are presented in Chapter 4. Chapter 5 provides answers to each research
question stated in Chapter 1 and discusses the quality of research outcomes. Chapter 6
concludes the thesis and provides an outlook for future work. Finally, Paper A, B and C
are appended.
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CHAPTER 2
Frame of Reference
This thesis is not limited to a single scientific field but rather cuts across elements of
several fields. The aim is to adapt design thinking and product development approaches,
mainly thus far employed in the manufacturing industry, into the context of pharmaceuti-
cal product and production development of customized pharmaceutical products. Hence,
relevant theories and concepts that this thesis builds upon originate in product design and
development and personalized medicines. This chapter describes these relevant theories
and concepts and concludes with the perceived gaps with respect to the development of
personalized medicines.
2.1 Personalized medicines
[Govender, 2019] compiled the characteristics of a patient that shall be considered to
enable customized product design, since these characteristics may cause a variability to
drug response and, consequently, the therapeutic outcome. A conceptual illustration of
the connection between patient characteristics and product design parameters can be seen
in Figure [Govender, 2019]. These characteristics are divided into three main domains,
namely the biological, behavioural and environmental. Biological characteristics refer to
patient attributes such as gene encoding, allergies and intolerances or age. Behavioural
characteristics refer to attributes including administration difficulties and adherence, and
environmental characteristics refer to attributes including food and alcohol habits. How-
ever, the respective dimension cannot be considered in isolation and hence, [Govender,
2019] introduces a dimension crossing the other dimensions of characteristics, the pa-
tient preference dimension. The patient preference dimension is aiming at demonstrating
the complex interaction between the different dimensions. [Govender, 2019] further ex-
plained this complex interaction by providing an example of an ageing population that
require an ease of handling the drug product, but simultaneously, the drug product need
to comply with physiological factors such as age and organ functions.
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Figure 2.1: The dimensions of patient characteristics and the correlated design
parameters of customized drug products [Govender, 2019].
This complex set-up of interacting patient characteristics should then be translated
into design parameters of the drug product to enable customized treatments. These design
parameters are the active pharmaceutical ingredient, the dose strength, the release rate of
the drug from the product complex, the formulation, sensory attributes referring to, for
example, the taste and smell of the drug product and finally, the dosage form appearance,
i.e. a flexible product size.
By designing the product according to these design parameters for the individual pa-
tient, the therapeutic outcome can be enhanced, i.e. the safety and efficiency of the treat-
ment. However, for these products to reach the patient, affordable manufacturing and
distribution of these products is required. Flexibility is not only required from a prod-
uct design perspective, referring to the design parameters to be considered for product
customization but also, an evident consequence of product customization is the increas-
ing number of product variants and the decreasing production volumes [Govender, 2019].
The following section will describe approaches to product design and production system
design discussing customization.
2.1.1 Pharmaceutical product and production design
approaches to customization
Pharmaceutical product design and production design research in the context of personal-
ized medicines have been emerging as a response to opportunities of product customiza-
tion.
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Product design
Current commercial product designs, such as multiple unit dosage forms, i.e. modular-
ized tablet designs, pellet-based dosage forms and mini-tablets, have been discussed as
enablers for personalized medicines. These product designs have especially been studied
as dosage forms facilitating treatment of pediatric and geriatric patients. Additionally, the
enabled opportunity of flexible dosing has been discussed [Aleksovski et al. 2015,Tissen
et al. 2011, Klingmann et al. 2013, Bonhoeffer et al. 2018]. However, studies of the full
benefit of multiple unit dosage forms as enablers of a mass customization-paradigm of
pharmaceutical products cannot be found.
Scored tablets, i.e. tablets with a cut on the face to make tablet splitting convenient,
is another commercially available product design. These tablets are produced to offer pa-
tients the opportunity to adjust the dose and thus, enabling some level of customization.
Tablet splitting is also facilitating administration difficulties as especially children and el-
derly have difficulties in swallowing tablets and capsules and as a result, tablets are split
into halves [Standing and Tuleu, 2005]. Most scored tablets available may be split into
two or four subunits [Quinzler et al. 2006]. However, splitting can lead to inadequate dos-
ing or tampering with the embedded release properties built in the tablet and can thus lead
to poisoning [Wening and Breitkreutz, 2011]. In addition, [Wening and Breitkreutz, 2011]
argued that a tablet split into only four doses is uncertain to be sufficient for customization.
Novel product designs are emerging in the literature to enable personalized medicines,
one such example being orodispersible films. Orodispersible films are solid state drugs
designed to disintegrate in the oral cavity and hence, forming a solution or suspension
in the mouth. These drug products suit pediatric and geriatric patients since the design
facilitates a convenient administration [Slavkova and Breitkreutz, 2015]. Additionally,
orodispersible films are stable in their solid forms and can be cut into desirable pieces,
hence supporting dose flexibility [Visser et al. 2015]. Widespread commercial imple-
mentation lacks evidence.
Production design
Additive manufacturing has been much studied as a technology of providing customized
product designs. In a computer model, the matter can be arranged as desired [Goyanes et
al. 2015]. Hence, product design can assume whatever form and [Norman et al. 2017]
argued that there are hardly any limits to customization with an additive manufacturing
approach. Additive manufacturing has proven to be a viable technology in the pharma-
ceutical production context. For example, FDA recently approved a 3D-printed product
[U.S. Food and Drug Administration, 2016]. However, the success of commercial pro-
duction in the context of personalized medicines lacks support.
Continuous technologies is another manufacturing technology on the rise and a con-
sidered viable for enabling customized pharmaceutical products. Continuous manufac-
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turing technologies have been discussed advantageous from the ability to respond to
variations in production volumes and variants, which will be a consequence of product
customization. Further, the discussions have extended to the supply chain networks of
the pharmaceutical products and continuous technologies as enablers for handling the
increasing number of product variants [Lee et al. 2015, Srai et al. 2015, Mascia et al.
(2013)]. These studies conducted still considered the product design remaining in the cur-
rent one-size-fits-all-paradigm and focused on adjusting the current manufacturing plat-
forms. There are uncertainties regarding how far the current mass production platforms
can be stretched to enable satisfactory customization.
[Wilson, 2016] addressed limitations of the current manufacturing platforms of phar-
maceutical products to enable customization in an economically feasible manner. The cur-
rent manufacturing platforms are not designed nor optimized for customization paradigm.
The process flow is inefficient due to various unit operations performed and the different
efficiencies of these unit operations. Further, other crucial activities of pharmaceutical
production, such as set-up, cleaning and quality assurance, strengthen inefficiency. Due
to strict requirements of the quality of pharmaceutical product while still employing batch
processing, tedious cleaning activities need to be performed to ensure no left-overs from a
previous batch. Additionally, different types of products require varying types of process-
ing and hence, set-up activities are performed to adjust processing equipment accordingly.
Further, the quality assurance process which mainly consists of testing the quality of a
sample off-line at a laboratory, additional activities besides product processing account
for longer times and hence, a customized-paradigm in which the number of increasing
product variants is coming down the pipeline cannot sufficiently be employing current
manufacturing platforms. Customization to be technically realizable and economically
feasible hence lacks evidence.
Current approaches to pharmaceutical product customization are mainly presented
from two detached ends. Either, the product design is discussed as an enabler for per-
sonalized medicines, i.e. approaches to enhance the therapeutic outcome of the patient,
or the production system design is discussed, i.e. approaches to respond to variable pro-
duction volumes and the increasing number of product variants. However, to enable mass
customization of pharmaceutical products, and integration of patient-driven product de-
sign, which optimizes the therapeutic outcome of the patient, and a production system
design enabling the production of these products in an economically feasible manner is
required. As [Wilson, 2016] pointed out, the strong connection between the pharmaceu-
tical product formulation and manufacturing need to be thoroughly understood to enable
pharmaceutical product customization.
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Figure 2.2: The product and production development process described
by [Suresh and Basu, 2008].
2.2 Product and production development in the phar-
maceutical industry
Even though the strong correlation between formulated drug product design and manufac-
turing process is required to be understood to enable pharmaceutical product customiza-
tion according to [Wilson, 2016], the nature of the current pharmaceutical product and
production development process might not support increasing this understanding. The
current product and production development process of pharmaceutical products takes
upon a sequential approach, see Figure 2.2 for an overview. A sequence of scale-ups is
still a reality and performed according to the success level in clinical trials. Addition-
ally, the product and production development process is governed by empirical laboratory
work and hence, has been described as a tedious and resource consuming process [Suresh
and Basu, 2008].
Some concurrency when developing the formulated drug product and the manufactur-
ing process occurs at a laboratory scale. The production process is further developed as
a scale-up procedure from an early safety assessment or clinical trial to finally reaching
the commercial manufacturing level of production. The process is developed providing
for the amount of material required at the current clinical trial phase. Sources report
that about a 10% success rate can be expected from the clinical trials [Suresh and Basu,
2008, Siew, 2017] hence, making larger efforts of developing production systems is of
secondary priority. Not only has scaling-up proven to complicate the development of pro-
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duction processes, but the development of robust manufacturing processes has been left
to a secondary focus. Additionally, once a sufficient production process has been found, it
is frozen early to enable process validation and then starting to produce the product com-
mercially. Making changes to validated production processes is also a tedious activity due
to strict regulations of pharmaceutical production.
Not only is the product development process considered tedious for the current mass
production paradigm but also, to enable development of customized product designs and
the production systems of these, tools to support efficient product and production devel-
opment is needed. [Suresh and Basu, 2008,U.S. Food and Drug Administration, 2013] has
expressed a need for science and engineering-based tools to enable predictive and cost-
efficient development of pharmaceutical product and production processes. The product
and production process behavior needs to be predictable to facilitate the current product
and production development process.
2.3 Product design and development
Product design is a process of creating, developing or constructing a product, system,
component or process. The reason for conducting product design activities is to meet
the desired needs of customers or stakeholders, and the product, system, component or
process are the means through which to meet these needs. Product design is an inter-
disciplinary process where fundamental elements include activities such as defining, syn-
thesizing, constructing, testing and assessing, and where science and engineering are ap-
plied to provide the means for meeting the needs defined [Pahl and Beitz, 1995].
Several authors have proposed frameworks for generic product design and develop-
ment such as [Pahl and Beitz, 1995], [Roozenburg and Eekels, 1996] and [Ulrich and
Eppinger, 2012], see Figure 2.3 for the product development process proposed by [Ulrich
and Eppinger, 2012]. The common denominator of these frameworks is a proposal of
a systematic approach to develop products. A generic product development process con-
sists of activities including product planning where the market need is defined and the end
result of the product development project is clarified. A concept development phase aims
at developing sets of concepts to widely search for candidate solutions to satisfy the mar-
ket need defined at the start of the product development project. This set is quite rapidly
narrowed down to further detail a concept with elaborate information regarding product
functions, architecture, subsystems and components, the product geometry and material
choices. Activities such as product construction and testing is performed as well as final
design refinements. The final activity is a production ramp-up to test the production of
the product with the intended equipment. The ramp-up is usually a stage-wise procedure
before reaching a final manufactured product.
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Figure 2.3: The generic product development process by [Ulrich and Eppinger,
2012].
2.3.1 Integrated product development
The sequential product development process induces a risk of prolonged lead-times. In
the sequential approach, usually an activity is finished before moving on to the next one.
This type of progress may require iterative loops to previous activities when increasing
knowledge about the production, market and product design is acquired and hence, the
choices made early are not sufficient anymore. [Andreasen and Hein, 1987] proposed an
integrated product development process, see Figure 2.4, to facilitate a parallel conduction
of development activities between the product design, production design and marketing
disciplines. An integrated approach enables a continuous monitoring of the market need
and the customer, simultaneously as the product and production system is designed and
thus, promotes a continuous information flow across these disciplines. Hence, information
from a discipline becomes faster available to be addressed by another discipline.
2.3.2 Concurrent engineering
Concurrent engineering (CE) is a philosophy with which to perform product design and is
strongly related to the integrated product development process by [Andreasen and Hein,
1987]. CE is mainly an organizational approach but can describe the product development
approach as well. CE thinking to design parallelizes the activities of product design and
production design disciplines. Concurrently performed design has proven beneficial to
a sequential approach because of promoting simultaneous decisions regarding, and mis-
matches in-between these disciplines can be avoided [Prasad, 1996].
[Sapuan and Mansor, 2014] emphasized the importance of introducing CE into com-
posite product design. Not only is CE regarded important because of the frequent cus-
tomization need of composite products, which requires early decisions regarding materi-
als and manufacturing-specific considerations, but also because a thorough understanding
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Figure 2.4: The integrated product development process by [Andreasen and Hein,
1987].
of material properties and the impact of these properties on production processes are re-
quired. [Sapuan and Mansor, 2014] further provided a review of CE implementation in
the industries of composite products and concluded that implementation into these indus-
tries has been performed to a limited extent. No references to the pharmaceutical industry
could be found.
Set-based concurrent engineering
Set-based concurrent engineering (SBCE) is a product development philosophy which
adopts the concurrent approach to design. However, in contrast to the conventional prod-
uct design and development, an early choice of a single design solution which is iterated
until it meets the specifications of the product, system or process, the set-based design
philosophy emphasizes the establishment of sets of alternative design solutions which are
with increasing information systematically narrowed down until a single feasible solution
is found [Sobek et al. 1999]. Figure 2.5 provides a conceptual illustration of the difference
between a generic product development process of [Pahl and Beitz, 1995, Ulrich and Ep-
pinger, 2012] and the set-based approach by [Sobek et al. 1999]. The illustration is trying
to emphasize that both approaches work with sets of solutions until the concept develop-
ment phase, but the approach of [Sobek et al. 1999] works with sets of solutions further
into the product development process, whereas the generic product development process
makes an early choice of concept that is refined in iterations. The product development
process in the pharmaceutical industry resembles the generic product development pro-
cess from the product development phase of product formulation.
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The SBCE has received attention in the past decades as the philosophy of product
development that enables a fast process resulting in a qualitative end product [Kennedy
et al. 2008, Ward and Sobek, 2014]. [Bernstein, 1998] proposed a concrete approach to
SBCE and suggested activities including defining the design space of respective disci-
pline, finding the intersections between the design spaces of respective disciplines and
further, expanding the design space through collaboration between disciplines. The de-
sign space should systematically be narrowed down when increasing information about
the intersecting design space has been gained. And as a last activity, the feasible solution
shall be defined. [Raudberget, 2010] studied the practical implementation of SBCE in in-
dustry and suggested a set of guidelines and activities supporting SBCE. These guidelines
and activities include avoiding freezing a design solution early in the design process and
making a distinction between important and unimportant product specifications. Broad
targets for specifications considered important should be set, and the unimportant specifi-
cations should be left unspecified. Further, solution alternatives shall be eliminated on the
sound basis when enough information has been acquired. Finally, tools such as trade-off
curves, technical data and simulations should be used throughout the process on which to
base elimination decisions.
2.3.3 Platform-based design and product variety
Platform-based design is an approach to developing products with the same goal as SBCE,
i.e. to generate knowledge about sets of design solutions. However, SBCE is rather a
philosophy, whereas platform-based design is an approach with hands-on activities to de-
velop product platforms. Further, product platforms have been frequently adopted for the
purpose of generating sets of derivative products, i.e. product families instead of a single
feasible solution [Michaelis et al. 2013]. Product platforms have proven to accelerate
business by increasing the value to the customer. A customized product can be offered,
which makes the product attractive to the customer, but the customized product is con-
figured from a defined set of components and hence, economical feasibility is achieved
[Meyer and Lehnerd, 1997,Wortmann et al. 1996,Ho and Tang, 1998]. Product platforms
form a technology grounded in a common structure, the product architecture, and sets
of defined subsystems and components. The product architecture is a scheme informing
how the functions of a product are allocated to physical components and how these inter-
act with each other to provide for the overall function of the product [Ulrich and Eppinger,
2012], hence, the architecture informs how the components of the product should be or-
ganized in the configuration in order to generate a product variant. The components used
for configuring product variants can vary to provide derivative products, but the structure
is kept rigid [Meyer and Lehnerd, 1997].
Two types of product architecture are widely discussed as enablers of product vari-
ety. A modular product architecture, that is a product configured of modules that embed
product functions. These modules are defined with standardized interfaces and by adding,
subtracting or exchanging modules, product variety can be achieved [Fujita, 2002]. Scalar
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Figure 2.5: An illustration of the difference between a generic product develop-
ment process by [Pahl and Beitz, 1995,Ulrich and Eppinger, 2012] and a set-based
product development process [Sobek et al. 1999].
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product architecture is the second type of architecture enabling product variety. A scalar
product architecture has a rigid architecture and the components of the product are frozen
into a structure. However, a scalar architecture allows for adjusting the design parameters
of specific components, inside a defined functioning bandwidth of the component, and
hence, product variety can be achieved [Simpson, 2001].
Functional modeling
As described, the product architecture is the scheme of allocation of product functions into
components realizing the functions. Hence, functional modelling is an approach by which
to describe the architecture of products. A functional model describes what a product is
supposed to do which is the intended behaviour of a product [Gero and Kannengiesser,
2004].
EF-M tree modelling is an approach to functional modelling and builds on Function-
Means modelling originally developed by [Tjalve, 1976]. The overall function of the
product is expressed as a functional requirement (FR) to which a design solution (DS) is
defined. The DS realizes the function. Further, this DS can be described in its FRs and
similarly, DSs are found to the respective FRs. The FR and the DS follow a one-to-one
cardinality, but alternative DSs to an FR can be proposed. By doing so, alternative ap-
proaches to realize the functions of the product is achieved, thus creating variants of a
product, i.e. establishing sets of design solutions to a product. Function-means modeling
has been evolving over time and the EF-M tree modelling approach by [Schachinger and
Johannesson, 2000] adds an element of constraint (C). The purpose of the Cs are to limit
the functioning region of the FRs, thus informing the design space of the DSs realizing
the FRs. Function-Means Modeling can be used as a scalar approach to product variety
by defining a functioning bandwidth of the FRs and by adjusting the DS realizing the FR
to satisfy the functioning bandwidths, a variety of solution alternatives.
The CC method presented by [Claesson, 2006] is based on EF-M trees but encapsu-
lates the FRs and the DSs of the EF-M tree into independently functioning subsystems, or
CC objects. By introducing independently functioning subsystems, such subsystems can
be perceived as modules. Hence, a modular architecture is achieved. These modules can
be added to, subtracted from and exchanged. Similar scalar approach to product variety,
as with the Function-Means modelling, can be achieved with the CC method.
Both [Levandowski et al. 2014] and [Michaelis et al. 2015] connected the CC ob-
jects to the component tree of the product. The component tree describes the physical
components (CO) of the product that provides for the desired functions. The information
regarding the physical realization of the product is embedded in the CC objects, but by
expressing the component tree with respect to the COs dimensions, geometry and so forth
the product architecture can be better understood. Figure 2.6 shows a conceptual model
of the CC method redrawn from [Michaelis et al. 2015].
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Figure 2.6: An illustration of the CC method by [Claesson, 2006], redrawn
from [Michaelis et al. 2015].
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2.4 Product value
The core of developing products shall be to increase the perceived product value of the
customer or some other stakeholder. There are numerous definitions and approaches to
describe product value. As mentioned, product customization can be seen as an approach
by which to increase the value to the customer, by offering a product tailored to customer
needs. [Lindstedt and Burenius, 2003] defined product value as the ratio between the per-
ceived benefits to the customer and the expenditure of the customer, expressed in time,
money or effort. Simply, a product offering additional benefits to a customer at a lower
cost is considered embracing a higher value.
The concept screening matrix by [Ulrich and Eppinger, 2012] developed from the
concept selection method first introduced by [Pugh, 1990] is a more concrete approach
by which to describe the value of the product compared to the approach by [Lindstedt
and Burenius, 2003]. The concept screening method is an approach by which to perform
a qualitative relative comparison of concepts toward a reference concept. The perfor-
mance of a concept is compared to the reference concept with respect to chosen perfor-
mance criteria. These performance criteria can be seen as criteria indicating the relative
value of the respective concepts. However, the choice of value-indicating criteria is left
to the researcher. Value assessment as proposed by [Pahl and Beitz, 1995] and the re-
lated approach of concept scoring matrix by [Ulrich and Eppinger, 2012] suggests further
describing the value-indicating criteria on quantitative scales and developing scoring sys-
tems to assign each concept scores depending on how well these concepts perform on
each value-indicating criteria. Further, [Pahl and Beitz, 1995] and [Ulrich and Eppinger,
2012] suggests assigning weights to the value-indicating criteria to enable the promo-
tion of concepts performing better on criteria judged more important. These approaches
require further developed concepts to enable sufficient performance assessments of the
concepts with respect to the criteria compared to the development level required for the
concept screening matrix. However, the approaches by [Pahl and Beitz, 1995] and [Ulrich
and Eppinger, 2012] can provide for more accurate comparisons between concepts than
the concept screening matrix can.
The feasibility of customized pharmaceutical products have been assessed but these
approaches have mainly acquired a narrow economic focus. The cost-efficiency of phar-
maceutical product customization has been discussed for example by [Hatz et al. 2014]
and [Srai et al. 2015]. However, the core purpose of the pharmaceutical product, which is
to treat people and hence, bring human and societal benefits, is overshadowed by this nar-
row economic focus. Approaches with which to assess the value of products expanding
beyond the narrow economic perspective has been proposed by studies conducted in the
aerospace industry by for example [Bertoni et al. 2015] and [Hallstedt et al. 2015]. The
proposed approach to value assessment integrates a full sustainability perspective as value
indicators, that is including the social, environmental and economic dimension when as-
sessing the value of products. Hence, the societal benefits of the products is incorporated
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into the product value.
2.5 Results of literature analysis
A review of existing literature on approaches to pharmaceutical product customization
and pharmaceutical product development resulted in a number of research gaps, which
are presented below. Further, theoretical elements to address these gaps have been iden-
tified through the literature review, considering product development approaches in the
manufacturing industry. These theoretical elements identified will be presented.
The following research gaps have been identified:
• The approaches to address the emerging need for mass customization of pharma-
ceutical products are either focusing on product design or production system de-
sign. To enable mass customization of pharmaceutical products the connection
between the patient-centric product design and production system needs to be thor-
oughly understood.
• There is a need for science and engineering-based tools enabling the development
of pharmaceutical products and the corresponding production systems in a predic-
tive manner. The current product and production system development approach of
pharmaceutical products is mainly based on a sequential, experimental procedure
from scale-up to scale-up. Not only is this a tedious and time-consuming process
for pharmaceutical product development in the current mass production paradigm,
but also a process such as is not believed to be sustainable for a mass customization
paradigm.
• The value of pharmaceutical product and production system designs supporting
customization have embraced a narrow economic focus. This overshadows the
core purpose of a pharmaceutical product, i.e. to treat people and hence, bring
societal benefits.
• Finally, multiple unit dosage forms have been discussed as enablers for personal-
ized medicines but the full benefit of these product designs as enablers for a mass
customization-paradigm has not been clarified.
Literature analysis
[Wilson, 2016] stated that to enable pharmaceutical product customization, the connec-
tion between the product formulation and the production need to be thoroughly under-
stood. Integrated approaches to product development such as CE have proven beneficial in
the manufacturing industry for ensuring a sufficient understanding of the product and pro-
duction system design simultaneously, and most importantly, the interaction in-between
these processes [Prasad, 1996]. Hence, concurrent engineering principles will be adapted
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in this thesis to explore the opportunity of providing a connection in-between the product
and production system design of pharmaceutical products.
As described by [Suresh and Basu, 2008, U.S. Food and Drug Administration, 2013]
a need for science and engineering-based tools are required in the pharmaceutical prod-
uct and production development to improve a tedious, sequential and laboratory-based
development process. The desire is for tools provide for predictive simulations to en-
able efficient concurrent development of pharmaceutical product and production system.
SBCE has been a successful product development philosophy in the manufacturing indus-
try with regard to the ability to develop qualitative products fast [Ward and Sobek, 2014].
Platform-based design has supported mass customization in the manufacturing industry,
and even improved business [Wortmann et al. 1996, Ho and Tang, 1998]. Hence, SBCE
principles and platform-based design approaches are adapted to develop methodologies
by which to design integrated product and production system platforms for pharmaceuti-
cal products to support customization and simultaneously enable prediction of product or
production system behaviour.
To enable product design assessment of pharmaceutical products, supporting cus-
tomization, that incorporates considerations of societal benefits, inspiration from approac-
hes by [Bertoni et al. 2015] and [Hallstedt et al. 2015] will be taken. [Bertoni et al. 2015]
and [Hallstedt et al. 2015] proposed approaches by which to integrate a full sustainability
perspective, including the social, environmental and economic perspectives, to perform
value modelling. However, the approaches by [Bertoni et al. 2015] and [Hallstedt et al.
2015] employed the concept of net present value, and hence, required a translation of
value criteria into monetary metrics. Thus, the concept screening matrix, allowing for a
qualitative comparison between product concepts will be adapted in the context of phar-
maceutical products to eliminate the need for translation into monetary metrics.
Since the multiple unit dosage forms have been discussed as enablers for customiza-
tion [Aleksovski et al. 2015, Tissen et al. 2011, Klingmann et al. 2013, Bonhoeffer et
al. 2018], each study will incorporate multiple unit dosage forms as a case to generate
knowledge about these in the context of pharmaceutical product customization.
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CHAPTER 3
Research Approach
Design can refer to an object or product, tangible or intangible, such as a chair or a web-
page. Design can also refer to activities a researcher performs to create objects as well as
generate knowledge about objects. In the latter case, the objective of generating knowl-
edge as an activity is to change an existing situation of an object to a desired one [Simon,
1996]. To achieve a change in the existing situation of an object into a desired one a
support is required. The knowledge acquired when performing design activities in order
to generate knowledge about objects can be transformed into practical implementation to
develop such designs (such designs referring to objects or products). This transformation
is achieved with the aid of the developed support.
Design research can be defined as ”generating knowledge about design and for de-
sign” [Horva´th, 2001]. On a comprehensive level, design research has two aims. The first
aim of design research is to establish the support, i.e. methods, methodologies, tools and
so forth to improve the performance of design activities, a practical outcome of design re-
search. The second aim of design research is to increase the understanding of design. Ide-
ally, these two aims, the establishment of practical tools to support the conduct of design
activities and the activities leading to an increased understanding of design, are integrated
and considered jointly. The integrated conduct of activities supports the achievement of
the overall aim of design research [Blessing and Chakrabarti, 2009].
3.1 Frameworks for design research
As design research has a two-fold purpose of both understanding design and practically
improving designs, an integration of multiple fields of science is not only required, but
also a vast cognitive and psychological effort. Hence, structuring design research is es-
sential for the researcher to advance understanding [Eckert et al. 2003]. For design re-
searchers, a few research frameworks have been established to support the researcher in
the research activities to maximize the probability of successful outcomes from research
projects. A successful outcome of design research implies a valid result in a generic, the-
25
oretical and practical sense [Blessing and Chakrabarti, 2009, Eckert et al. 2003]. This
section will provide an overview of different frameworks for design research and clarify
the research approach taken to conduct research in this thesis.
3.1.1 Paradigms of Design Research
[Warell, 2001] described two types of design research paradigms which were originally
presented by [Jørgensen, 1990]. These two design research paradigms, problem-based
and theory-based, and respective approach are illustrated in Figure 3.1. The origin of the
research topic initiation differentiates these design research paradigms. The researched
topic may have been initiated by a practical problem during the conduct of design work
and thus, a problem-based research approach is suggested as research approach. On the
other hand, the researched topic might have also been initiated by an insufficient availabil-
ity of theories and methods with which to conduct design work and thus, a theory-based
research approach is suggested. Both approaches aim for the same final goal regardless of
the point of research initiation, that is to acquire new scientific knowledge, develop meth-
ods into which to implement this acquired knowledge and finally, transfer the acquired
knowledge into practical results.
According to [Jørgensen, 1990], the problem-based research approach starts with a
practical problem of conducting actual design work and is followed by empirical work to
discover structures of causalities. The problem-based approach is governed by empirical
research activities to gather external, real-world knowledge of design processes and prod-
ucts. The theory-based approach is highly characterized by theoretical activities, such as
combining existing theoretical elements into new theories, theories that are perceived to
be lacking, and hence, promotes development of theoretical constructs [Warell, 2001].
The steps of each research approach are rarely conducted in a sequential manner,
but the approaches are rather iterative and research activities are conducted in several
loops. Further, according to [Warell, 2001], most design research projects collect elements
from both paradigms to various degrees depending on the project, i.e. a constant ongoing
interplay between the problem-based and theory-based approaches occur. This interplay
is illustrated by the arrows pointing in various directions in Figure 3.1.
3.1.2 Design Research Methodology
[Blessing and Chakrabarti, 2009] developed the Design Research Methodology (DRM),
a framework with which to conduct design research. The framework consists of four
distinct stages with various research activities performed at each stage. Figure 3.2 presents
the stages of DRM and further, the means of conducting research and the main outcome
of each stage is clarified. A short description of each stage follows.
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Figure 3.1: The two types of research processes according to [Jørgensen, 1990],
redrawn from [Warell, 2001].
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Figure 3.2: The Design Research Methodology, redrawn from [Blessing and
Chakrabarti, 2009].
Research clarification
The first stage of the DRM is the research clarification stage. The main outcome of the
research clarification stage is a formulated overall goal of the design research project and
a further elaboration of goals into criteria. These criteria will assess the success of the
research project. At this stage, research questions are formulated.
To formulate the goal of the research project, an understanding of the initial stage to
be changed is required. Further, a vision of the desired stage to aim for when conducting
design research activities is specified. This stage is governed by literature studies and
analysis.
Descriptive study I
The second stage of the DRM is the descriptive study I stage. The main outcome of
this stage is a better understanding of the research goal and criterion to determine the
success of the research project. By complementing the analysis performed during research
clarification with additional literature studies and empirical data analysis, the knowledge
of the current situation and the criteria to be studied is increased. This stage can embrace
a comprehensive or review-based nature depending on the research project.
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Prescriptive study
The prescriptive study stage has the purpose of establishing the support to facilitate de-
sign work both in practice but also as a means of increasing the understanding of design.
Preferably, this support contributes to both practical applications and to increased knowl-
edge about design. This support can assume the nature of a tool, method, methodology
and so forth.
At the prescriptive study stage the researcher’s creativity, assumptions and experi-
ences play a fundamental role, from which the support is established. This support should
provide the means of achieving a change of the existing into the desired situation as for-
mulated in the research clarification stage.
Descriptive study II
The final stage of the DRM is the descriptive study II stage. The main outcome of this
stage is an evaluation of the support established in the prescriptive study stage. An eval-
uation of how the existing situation has been changed to the desired situation is performed.
The descriptive study II stage has two objectives: to evaluate the applicability of the
support and to assess the success of the support. The success of the support is assessed
with regard to the success criterion formulated in stage research clarification and refined
in stage descriptive study I. This assessment is performed by conducting empirical studies
to test the support.
DRM is presented stage-wise but it is a highly flexible framework. As illustrated in
Figure 3.2, arrows are pointing in several directions. The researcher is given the freedom
of executing each stage in the preferred order and iterate stages several times if desired.
Stages can be left out if judged unsuitable to the nature of the research project.
3.1.3 Other design research frameworks
[Eckert et al. 2003] proposed a framework to design research which to a large extent cor-
responds to the DRM framework by [Blessing and Chakrabarti, 2009]. However, [Eckert
et al. 2003] not only suggested a separation of the DRM stages into additional stages
depending on the nature of the research activity performed during a stage. For example,
a separation of descriptive study I into activities, such as empirical studies and theory
formation, was proposed. Additionally, [Eckert et al. 2003] chose the perspective of
stressing the importance of evaluating each outcome of research activities conducted and
hence, integrated an additional element of evaluation of each research activity as a pri-
mary activity. The aim of developing this framework was to better address the perceived
problem of design research, meaning the multidisciplinary nature of design research lead-
ing to the difficulty of predicting the consequences of implementing research findings in
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an industrial context. Hence, the validity of each research activity is continuously moni-
tored throughout the stages of research. Naturally, the element of evaluation is included
in the DRM framework but embedded in the stages of the framework.
The interactive model by [Maxwell, 2013] is a framework for qualitative research
design which emphasizes a parallel approach to research and which argues that research
activities, such as collecting and analyzing data, developing theories, refining research
questions and so forth, each affect one another and are also more or less are conducted in
parallel. Moreover, the interactive model is a model both of a research project and for a
research project, i.e. a model that facilitates researchers’ understanding of their research
projects but that likewise facilitates the conduct of the research project. Other frameworks
generally express how to conduct activities within a research project.
3.1.4 The applied research approach
This licentiate thesis fits into the theory-based paradigm as described by [Jørgensen,
1990]. It is argued that the current product and production development process of
pharmaceutical products is a sequential, mainly laboratory-based, time and resource-
consuming approach and hence, new theories regarding engineering-based development
approaches of products proven efficient shall be brought in. This research project takes
inspiration from theoretical elements regarding product and production development pro-
cesses in other fields, mostly the manufacturing industry, and combines these theoretical
elements into new theories that are applied in the context of product and production de-
velopment of pharmaceutical products.
The research activities performed can be aligned with the parallel research approach
as described by [Maxwell, 2013], i.e. activities have not been conducted in a sequen-
tial manner but the activities have instead been ongoing simultaneously and affected one
another. However, to structure the research conducted, the DRM framework is used to
conveniently communicate each research activity performed but also to remind oneselves
of the possible types of activities that must be performed in order to maximize the proba-
bility of a successful outcome of the research project.
[Blessing and Chakrabarti, 2009] presented seven types of research projects, which
differ from each other with respect to the stages treated in the DRM framework, but also
differ from each other with respect to the nature of the stages treated. Each appended
paper resembles the research project type proposed by [Blessing and Chakrabarti, 2009]
outlined in Figure 3.1.4. The stages of the DRM framework treated in each paper consist
of the research clarification, descriptive study I and prescriptive study.
This type of research project, as described in Figure 3.1.4, was judged to describe
the research conducted in each appended paper due to the nature of the research project.
As mentioned, this research is judged to fit into the theory-based paradigm approach as
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Figure 3.3: The applied research approach, redrawn from [Blessing and
Chakrabarti, 2009] and complemented by each paper to illustrate the extension
of studies regarding the DRM stages.
described by [Jørgensen, 1990]. Further, the research questions aim at answering the
question of how rather than describing an as-is stage answering the question of what, thus
taking on an exploratory nature. The theory-based research approach paradigm of syn-
thesizing theoretical elements into new theories and the exploratory nature of the research
questions are considered justifying the review-based descriptive study I stage, which aims
at reviewing theories of product development in other fields of research. Further, a more
extensive prescriptive study stage, creating new theories, establishing models and so forth,
is considered justified for this type of research project.
So far, the models developed are still at an infant stage and hence, the prescriptive
study stage is marked as ”initial” but more elaborate work on this stage will be performed
later and further, the descriptive study II stage shall be addressed in the future. A descrip-
tion of the applied research approach of each paper follows.
The applied research approach of Paper A
Paper A addresses initially RQ1, How can pharmaceutical product designs be established
to support product customization and the consequences of these designs for the produc-
tion assessed? The research clarification stage was comprised of a broad literature review
and as a result, a two-fold research gap was established. First, a gap of methods to system-
atically designing pharmaceutical products to support mass customization in a concurrent
manner was defined. The second gap addressed the lack of explored benefits of modular-
ized tablet designs as enablers for personalized medicines.
The next stage of execution of the DRM framework was the descriptive I stage. This
stage consisted of theory developing activities. Theoretical elements of systematic mod-
elling of product design approaches in the context of product customization in manufac-
turing industry were studied, i.e. platform-based design approaches. Hence, the con-
figurable component (CC) method, i.e. a platform-based design approach founded on
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product architecture modelling by [Claesson, 2006] was chosen as a theoretical element.
The CC method was adapted into the context of pharmaceutical products to establish
customized product designs by expressing the architecture of these products and further
developing them into platforms. Further, studies regarding approaches with which to
assess these product designs from a production point of view were conducted and the
complexity factor by [Pugh, 1990] was adopted to provide an indication of product design
consequences for production.
The prescriptive study stage was conducted by synthesizing the theoretical elements
adapted in the theory development-study into a methodology of proposing systematically
designed pharmaceutical products by expressing the architectures of these and further
developing the product architectures into product platforms. Hence, product designs sup-
porting customization can be established. Further, this methodology proposes an approach
to assess the consequences of these product designs for production. The purpose of this
methodology is to contribute to a design tool for pharmaceutical products to be later im-
plemented in industry. Lastly, the applicability of this methodology was tested in an ex-
ploratory manner to simulate and understand the benefits of modularized tablet designs.
The purpose of the methodology application was to contribute to knowledge regarding
modularized tablets as enablers for personalized medicines and hence, addressing RQ4,
How can modularized tablet designs enable personalized medicines?
The applied research approach of Paper B
Paper B addresses RQ2, How can the value of pharmaceutical product designs support-
ing customization be assessed? The study in Paper B builds further on the approach of
developing product platforms for pharmaceutical products by applying the CC method
proposed in Paper A. The study was initiated by a realization that no existing methodolo-
gies emphasizing the benefits of pharmaceutical product designs supporting customization
could be found. The research clarification stage comprising a literature review aimed at
defining pharmaceutical product designs from a value-perspective confirmed the lack of
methodologies with which to conduct an assessment of pharmaceutical product designs
satisfactorily. Assessments of pharmaceutical product designs were mainly performed
from an economic point of view disregarding the core purposes of pharmaceutical prod-
ucts, i.e. to treat people, hence bringing human and societal benefits.
Hence, a descriptive study I stage aimed at studying theoretical elements from man-
ufacturing industries to be inspired by approaches defining product value. Methods with
which to assess value from a full sustainability perspective, i.e. social, economic and
ecological, were adopted as theoretical elements. More specifically a framework for sus-
tainable product development, SLCA2.0 by [Villamil et al. 2018], was adapted to perform
a life cycle assessment of pharmaceutical products from a full sustainability perspective.
Additionally, methods for value modelling were studied and finally, the concept screen-
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ing matrix by [Ulrich and Eppinger, 2012] was adapted to enable comparative studies of
pharmaceutical product designs.
The prescriptive study stage further synthesized the methods into a methodology that
proposes an approach with which to develop pharmaceutical product designs supporting
customization and assess the value of these designs from a full sustainability perspective,
i.e. including the economic, environmental and social sustainability dimension. The ap-
plicability of this methodology was tested in the context of modularized product designs.
Simulations were performed to assess the consequences of modularized tablet designs on
perceived product value. Hence, these simulations aimed at addressing RQ4, How can
modularized tablet designs enable personalized medicines? , by generating knowledge
regarding the value of modularized tablet designs.
The applied research approach of Paper C
Paper C addresses further RQ1, How can pharmaceutical product designs be established
to support product customization and the consequences of these designs for the produc-
tion assessed? , as well as RQ3, How can the product and production system be modeled
so that the consequences of changing customer needs can be assessed? The study of
Paper C was initiated by a desire to further develop an approach to concurrent engineer-
ing of pharmaceutical products by focusing on a more elaborate integration of production
system design. A research clarification stage, governed by literature studies regarding
product development of personalized medicines and approaches to product customization
by adopting concurrent principles, resulted in a perceived gap of non-existing methods to
systematic concurrent engineering of customized pharmaceutical products.
The descriptive study I stage was comprised of literature studies to study theoretical
elements regarding concurrent engineering approaches for product customization. The
manufacturing industry was studied to acquire inspiration for approaches to concurrent
engineering and product customization. The SBCE approach to platform-based develop-
ment by [Levandowski et al. 2014] was adapted. A model of integrated product and pro-
duction platforms for pharmaceutical products was developed by adapting the approach
to SBCE and platform-based development. Further, a proposal for an approach to respond
to changing customer needs was developed by applying the producibility model by [Lan-
dahl et al. 2017,Madrid et al. 2016]. Hence, a dynamic model for developing customized
product and production system designs was established.
The prescriptive study stage consisted of activities of synthesizing the methods stud-
ied in the descriptive study I stage into a methodology. This methodology aims at fa-
cilitating the development of integrated pharmaceutical product and production system
platforms in a set-based manner and described an approach to respond to changes in
customer needs. The application of the methodology was presented in the context of a
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modularized tablet design to generate knowledge regarding the benefits of modularized
tablet designs as enablers for personalized medicines, hence addressing RQ4, How can
modularized tablet designs enable personalized medicines?
3.2 Research methods
This section describes the primary methods to conduct research. In this thesis, the pri-
mary methods employed have been reviewing the literature and synthesizing theoretical
elements into methodologies. Further, simulations have been performed to test the ap-
plicability of the methodologies and to generate knowledge regarding modularized tablet
designs as enablers for personalized medicines. Thus, illustrative case studies have been
carried out in the context of modularized tablet designs.
3.2.1 Literature review
Literature review has been used as a data collection method in the research project. Liter-
ature reviews have been conducted stepwise in each study of Papers A, B and C. The aim
of the literature reviews has been to create a comprehensive understanding of the prob-
lem of customized pharmaceutical product and production development activities either
being focusing on the patient-centric product design or on the production system design.
Successful approaches to mass customization of pharmaceutical products are not fully
explored. Further, studies to understand the product development process of pharmaceu-
tical products, being governed by experimental laboratory work in a sequential manner
and the modest focus directed towards production system development have been per-
formed. Hence, literature regarding pharmaceutical product development was analyzed
for the purpose of establishing research gaps.
Literature regarding product development in the manufacturing industry was reviewed
and analyzed with respect to phenomena describing successful product development philo-
sophies and approaches. Further, the analysis conducted included an assessment of these
philosophies and approaches ability to be adapted in the context of mass customization of
pharmaceutical products.
3.2.2 Methodology development
The collection of theoretical elements were synthesized into methodologies to address the
research gaps proposed as results of the literature reviews. SBCE principles were chosen
as a product development philosophy to enable the efficient assessment of sets of product
and production system variants. Methods synthesized into methodologies included, the
CC method [Claesson, 2006] and the EF-M tree modelling approach [Schachinger and
Johannesson, 2000]. The functional modelling nature of these methods was perceived
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advantageous for flexible product and production system design as well as the ability to
use these methods for platform modelling. Platforms have been proven to support mass
customization in the manufacturing industry. SLCA2.0 method [Villamil et al. 2018]
was collected to support an integrated approach for sustainable product development of
pharmaceutical products. And finally, the concept screening matrix [Ulrich and Eppinger,
2012] was adapted to enable a value description of customized pharmaceutical product
designs.
3.2.3 Simulation based case studies
Simulations have been employed to mainly illustrate the application of the developed
methodologies and hence provide initial validation by confirming that the behaviour of
the methodologies is sufficient according to the defined goals for developing the method-
ologies. Simulation studies have also been conducted to understand the opportunities
provided for the product and production development process of pharmaceutical products
by applying approaches employed in the manufacturing industry. For example, applying
SBCE principles to develop product and production system designs for pharmaceutical
products allows for rapid cause-and-effect simulations of various product designs and the
consequences for production. The main focus has been to develop platforms for product
and production systems of pharmaceutical products and hence, the software CCM [Claes-
son, 2006] which is a platform modelling software and enables modelling and simulation
of platforms, has been used. Due to the restricted capabilities of CCM [Claesson, 2006],
simulation support has additionally been provided by MATLAB .
Each study conducted, as described in the appended papers, demonstrates the appli-
cability of the methodology synthesized by performing an illustrative case study. These
case studies have been conducted in the context of modularized tablet designs to generate
knowledge about these designs as enablers for personalized medicines. The illustrative
case studies performed are of a qualitative nature, for example the application of methods
require qualitative studies, such as employing the CC method [Claesson, 2006] to design
flexible pharmaceutical products. The illustrative case studies are also of a quantitative
nature, experimental simulations have been conducted to generate knowledge about the
cause-and-effect of various design choices of modularized tablet designs and the conse-
quences of these designs on predefined criteria. The data used for the experiments have
both been of a fictitious nature and data gathered from empirical studies found in the
literature.
3.3 Research outcome quality criteria
Empirical validation of design theories has been proven a difficulty of conducting design
research [Roozenburg and Eekels, 1996, Buur, 1990]. [Roozenburg and Eekels, 1996]
described that the process of designing products cannot be repeated, and this can be un-
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derstood when considering the inter-disciplinary nature of design research that relies to a
large extent on the researchers knowledge, experience, creativity and the ability to con-
nect various scientific fields. [Roozenburg and Eekels, 1996] thus highlighted the conse-
quences of a non-repeatable design process; firstly, to prove that better research outcomes
would have been obtained with another research approach is a difficulty, and secondly,
proving that the research outcome by precise virtual repetition in a mathematical manner
is a difficulty due to the various number of factors affecting the result. [Roozenburg and
Eekels, 1996] even argued that proving the research outcome in a mathematical manner
might even be irrelevant.
Approaches to validation of design research has been proposed by numerous sources
[Creswell, 2014,Buur, 1990,Yin, 2009]. Two fundamental guiding questions that are con-
necting most of the validation approaches are did we do the right things? and did we do
things the right way? The first question relates to the validity and the second question to
the reliability of the design research outcome.
[Creswell, 2014] described validity as considerations of the research outcomes abil-
ity to describe the measured phenomena, including the trustworthiness and credibility of
the research outcome. [Almefelt, 2005] suggested transferability, i.e. the degree to which
the results can be generalized beyond the setting, an important concept to consider when
assessing validity of research outcomes. [Almefelt, 2005] further elaborated that, the re-
searcher has the ability to enhance the transferability by providing a careful description of
the study, the context, hypothesis proposed and so forth. Reliability of the design research
outcome considers concepts such as the consistency of the approach proposed and hence,
the reproducibility of research outcome [Creswell, 2014].
[Creswell, 2014] described procedures to ensure the validity of research outcomes
when performing quantitative research activities or rather, described threats to validity.
Thus, to ensure valid research outcomes, evidence supporting validity threat elimination
becomes important. Eliminating validity threats imply that the research conducted affects
the objective of research in an intended way and does not affect anything else. [Creswell,
2014] divides validity threats into two groups, internal and external validity threats. In-
ternal validity threats consider threats to the procedure of performing experiments, for ex-
ample, the sampling procedure and drawing correct inferences from results and so forth.
External validity threats consider threats to the generalizability of research results from
the experiment beyond the chosen sample.
[Buur, 1990] addressed the difficulty of validating design research by suggesting a
two-fold design research validation approach. The first part, denoted logical verification,
consists of activities including ensuring no internal conflicts between the theoretical ele-
ments synthesized into new theories and ensuring that the method derived from the theory
is consistent with the theory, i.e. consistency. Further activities include the ability of
explaining all relevant phenomena, observed in literature or empirically, with the theory
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proposed, i.e. completeness of theory. And final and last activity, the theory should be
able to explain the observations of the case studies performed. The second part of the re-
search validation approach by [Buur, 1990], denoted verification by acceptance, suggests
that theories proposed, and the methods or models derived from the theories, are valid if
accepted by experienced designers.
[Sargent, 2013] proposed a model for stepwise validation of simulation models. The
model by [Sargent, 2013] aligns with the intention of ensuring the validity and reliability
of research outcomes. Further, Sargent described the element of credibility as a part of
model validation, that is the confidence that the users of the model have in the model, as
well as the confidence in the information retrieved from the model. The level of credibil-
ity should increase with proper validation of the simulation model.
According to [Sargent, 2013], the aim of simulation model validation, i.e. activities
such as model verification and validation, is to ensure that the information retrieved from
simulation models are correct for their usage context. Verification implies that the sim-
ulation model is doing what the model is intended to do. Validation implies confirming
that the model performs according to a sufficient accuracy as intended in the predefined
context. Hence, the validity of a model is strongly linked to the context of model applica-
tion. If the model has been developed to answer certain questions, the model validity is
decided from the ability of the model to answer these questions.
The model for stepwise validation of simulation models by [Sargent, 2013] incorpo-
rates three vital elements to the development procedure of the simulation model and fur-
ther, the validation and verification in-between each developed element. The first element
is the problem entity, which is the system, product or phenomena for which a simulation
model is to be developed. The second element is the conceptual model. The conceptual
model can be a graphical, mathematical or logical representation of the problem entity
defined. The final element is the computerized model, which is the conceptual model
implemented into a computer. The validation procedure in-between each element of the
developed model consists of the following steps, conceptual model validation, computer-
ized model verification, operational validation and data validity.
Conceptual model validation is the procedure by which to validate the conceptual
model, i.e. to ensure that the conceptual model developed solves the problem entity for
which the model has been created. Activities of this step aim to ensure that the underlying
theories and assumptions for the model are correct and reasonable for the problem entity
defined. Computerized model verification is the procedure to ensure that the implementa-
tion of the conceptual model in a computer has been conducted in a correct manner. The
operational validation procedure ensures that the computer model used for simulations
can describe the model behavior to a reasonable extent in order to provide a solution for
the problem entity defined. Finally, the data validity step aims to ensure that the data
necessary for the three elements of model development are adequate and correct to solve
37
the problem entity, i.e. data for model building, conducting experiments on the model and
finally, providing a solution for the problem entity.
3.3.1 The applied research quality assessment procedure
A short summary will be provided to elaborate on which of the research quality crite-
ria described above are adopted to assess research outcomes of this thesis. The research
performed, as mentioned, has embraced a quantitative nature and to some extent qualita-
tive nature, hence the quality criteria for assessing research outcomes will be described
separately for qualitative and quantitative criteria.
Adopted qualitative research quality criteria
The criteria adopted in this thesis to assess the quality of research outcomes of qualitative
research is validity and reliability. The proposed methodologies are results from quali-
tative studies and are perceived as models but also as design theories and hence, validity
and reliability criteria proposed by [Creswell, 2014], [Sargent, 2013], [Almefelt, 2005]
and [Buur, 1990] is adopted.
To assess the validity of the proposed methodologies the ability of the methodolo-
gies to solve the problem entity that the model has been created for is assessed, described
as the conceptual model validation activity proposed by [Sargent, 2013]. Ensuring the
model sufficiency, aligns with the completeness criteria proposed by [Buur, 1990], i.e.
ensuring that the relevant phenomena observed can be explained by the proposed theory.
The transferability criteria, as proposed by [Almefelt, 2005], is used to evaluate the trans-
ferability of the proposed methodologies beyond the context for which the methodologies
were created. Credibility, i.e. the confidence the model user has in the model as well
as the information retrieved from the model as described by [Sargent, 2013], is used to
assess the methodologies. The verification by acceptance activity suggested by [Buur,
1990], i.e. the acceptance of the theories and models proposed by experienced designers,
is considered correlated to the credibility criteria and is discussed in this thesis.
Reliability is the second criteria according to which the proposed methodologies are
assessed. The reproducibility criteria as suggested by [Creswell, 2014] is discussed and
the correlated concept of consistency by [Buur, 1990], i.e. ensuring the synthesis of the-
oretical elements has been performed correctly and the methods are in agreement with
the theory. Computerized model verification as proposed by [Sargent, 2013] correlates to
these previously mentioned criteria as it emphasizes the importance correct implementa-
tion of the model into the computer thus this criteria will be adressed in this thesis.
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Adopted quantitative research quality criteria
As mentioned, the case studies performed during research adopts partly a quantitative
nature with experimental simulations conducted. Hence, criteria chosen to assess the
quantitative research outcomes are internal and external validity.
To discuss internal validity the sampling procedure of the population used for case
study simulations is assessed, which [Creswell, 2014] suggested as a threat to internal va-
lidity. [Sargent, 2013] discussed the operational validity, i.e. the ability of the computer
model to describe behaviour of phenomena sufficiently according to the problem defined,
which is considered correlated to internal validity. A correctly performed experimental
set-up shall reflect a correct behaviour of the model.
To assess the external validity the generalizability of the case study results beyond
the sample is discussed.
The quality of the research outcomes are discussed in Chapter 5.
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CHAPTER 4
Results
This chapter presents the results of the thesis within the scope of the aim and goal of this
thesis. A short summary of each study in the respective appended paper is provided with
the main motivation behind conducting the study. The important results of each Paper, A
to C, are highlighted. Complete descriptions of studies conducted and results obtained are
provided in the appended papers.
4.1 Summary of studies conducted
This section presents a summary of each study conducted paper-wise and the main moti-
vation behind the studies.
Paper A addresses RQ1, How can pharmaceutical product designs be established to
support product customization and the consequences of these designs for the production
assessed? The focus is to explore how pharmaceutical product designs supporting cus-
tomization can be established. The motivation behind conducting the study was the lack
of engineering-based design methodologies with which to develop pharmaceutical prod-
uct designs supporting customization and assessing the consequences of these designs for
pharmaceutical production.
The key contribution of Paper A is a proposal for a methodology to develop phar-
maceutical product designs by establishing the architectures of pharmaceutical products,
developing these architectures into product platforms and assessing the consequences of
these product designs with respect to manufacturing complexity. The architecting ap-
proach builds on the CC method presented by [Claesson, 2006] and the complexity factor
by [Pugh, 1990] serves as an indicator of manufacturing complexity. Further, the appli-
cation of the methodology is illustrated in the context of modularized tablet designs to
address RQ4, How can modularized tablet designs enable personalized medicines?
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Paper B addresses RQ2, How can the value of pharmaceutical product designs sup-
porting customization be assessed? and focused on the means to assess the value of a
re-designed pharmaceutical product supporting customization. The idea for Paper B was
initiated by the results of Paper A. In Paper A the performance of the pharmaceutical
product designs was assessed with respect to the number of product variants and the com-
plexity factor, but more elaborate approaches to assess the performance of customized
pharmaceutical products was a desire. Additionally, the narrow focus on an economic
perspective when assessing pharmaceutical product performance found in literature, fur-
ther confirmed the need for better value assessment approaches. This study focused on
performing more elaborate analyses on the value of pharmaceutical product designs, em-
phasizing the importance of treatment customization.
The key contribution of Paper B is a methodology to support design decisions regard-
ing pharmaceutical product designs from a value perspective. Furthermore, the method-
ology suggests a value-modelling approach where a full sustainability perspective, i.e.
including the social, economic and ecological sustainability dimensions, is adopted as
value assessment criteria. The applicability of the methodology is illustrated in the con-
text of modularized tablet designs to address RQ4, How can modularized tablet designs
enable personalized medicines?
Paper C addresses RQ1 and RQ3, How can the product and production system be
modeled so that the consequences of changing customer needs can be assessed? and fur-
ther elaborates on the research gap defined in Paper A regarding the need for engineering-
based design methodologies to concurrently develop pharmaceutical product designs and
corresponding production systems. The idea of Paper C was initiated by the desire of
elaborate approaches to consequence analysis of pharmaceutical product designs on the
production system.
The key contribution of Paper C is a methodology to concurrently develop integrated
product and production system platforms for pharmaceutical products to support the con-
sequence assessment of pharmaceutical product design choices for the production system.
Additionally, the methodology allows for dynamic platform modelling, i.e. responding to
changes in the established integrated platform that might occur due to a change in cus-
tomer needs. Further, the applicability of the methodology is illustrated in the context of
modularized tablet designs to address RQ4, How can modularized tablet designs enable
personalized medicines?
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4.2 Paper A: Product Architecture Management of
Medicinal Products
- An Integrated Function-Means Tree Approach
to Customizing Oral Dosage Forms
The purpose of Paper A was to develop a methodology for managing product architectures
of pharmaceutical products. A literature review showed emerging research addressing
personalized medicines. The research focus thus far has been directed towards empirical
attempts to customized product design or towards production system design assuming a
product design of the one-size-fits-all-paradigm. Concurrent approaches to product and
production system design supporting mass customization of pharmaceutical products are
lacking.
The methodology proposed in this Paper A focuses on a systematic approach to es-
tablish customized product designs of pharmaceutical products and suggests an initial
approach to assess the consequences of established product designs for manufacturing
complexity. Furthermore, the application of the methodology is illustrated in the context
of modularized tablet designs to generate knowledge on modularized tablet designs as an
enabler for personalized medicines.
4.2.1 Proposed methodology
The proposed methodology is presented in Figure 4.1. Traditional product design from
the one-size-fits-all-paradigm, such as a fully integral tablet design, provides the founda-
tion for the product architecture, i.e. a description of the product in terms of its functions.
Further, patient attributes serve as input and are refining the established functional model
of the product by translating these attributes into product functions. This translation is per-
formed by logical reasoning and supported by the literature. The CC method [Claesson,
2006] is applied to establish the architecture of the pharmaceutical product. The product
platform of the pharmaceutical product is modelled by complementing the product archi-
tecture with design parameters. For platform modelling and execution, the CCM [Claes-
son, 2006] and MATLAB softwares are used. The output of the methodology is a product
platform for pharmaceutical products. Additionally, through the execution of the product
platform, sets of product families are generated for which the performance is calculated.
In this study, the complexity factor by [Pugh, 1990] was used as an indicator of product
family performance with respect to manufacturing complexity.
4.2.2 Illustrative case study
To illustrate the application of the methodology, a modularized tablet design is introduced.
Further, the consequence for production from various modularized tablet designs is as-
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Figure 4.1: The proposed methodology of Paper A to develop customized phar-
maceutical product designs and assess the performance of these designs.
sessed. Cases were prepared to generate product families by platform execution. These
cases use various sizes of API modules from which to configure product variants, Case A
configures product variants of API modules of size 1 mass unit, Cases D and E use two
sizes of API modules, 1 & 5 mass units and 1 & 10 mass units, respectively, and case G
uses three sizes of API modules, 1, 5 & 10 mass units from which to configure product
variants. Each case uses filling modules of a single size for product variant configuration
purposes. The execution space of the product platform is defined as each dose step in-
between 1 and 100 mass units.
Figure 4.2 presents the results of the product family performance calculation. This
performance is displayed as the number of product variants on the primary axis (to the
left) for product families A, D, E and G. Additionally, to give an indication of the cost-
benefit of introducing modularized tablet designs and further, configuring product variants
from various sizes of modules, the results of performance calculations are presented as the
ratio between the number of product variants and the complexity factor on the secondary
axis (to the right). In Figure 4.2 the product families A, D, E and G have been organized
according to an increasing customization level (the number of product variants).
Conclusively, Paper A has successfully presented an approach to concurrent engi-
neering of product and production system designs of pharmaceutical products supporting
customization. This has been conducted by proposing a methodology for managing prod-
uct architectures of pharmaceutical products, developing these into platforms and assess-
ing the consequences of these established product designs on manufacturing complexity.
Further, the application of the methodology was illustrated in the context of modularized
tablet designs to generate knowledge regarding modularized tablet designs as enablers for
personalized medicines. Results in Figure 4.2 indicate that by the introduction of a few
44
Figure 4.2: Trade-off between the number of product variants and the ratio be-
tween the number of product variants and complexity factor in Paper A.
standardized modules from which to configure product variants, the number of product
variants increases rapidly. Further, the ratio between the number of product variants and
the complexity factor indicates that even though the complexity factor would be increasing
by introducing several modules as product configurational means, the complexity factor
is not increasing as fast as the number of product variants.
4.3 Paper B: Decision Support for Re-designed
Medicinal Products
- Assessing consequences of customizable prod-
uct design on the value chain from a sustainabil-
ity perspective
The purpose of Paper B was to establish a methodology with which to evaluate the value of
pharmaceutical product designs, more specifically, assessing the value change when a cus-
tomizable product design is introduced. A literature review showed that value modelling
approaches have not been applied in the context of personalized medicines. Value assess-
ments of pharmaceutical products have in general been limited to economic perspectives.
Additionally, environmental assessments of pharmaceutical products were found. Fur-
thermore, literature studies showed that these studies of pharmaceutical product value
conducted from an economic or environmental perspective were limited to a single value
chain phase, as no studies assessing the consequences of introducing customizable prod-
uct designs on the whole pharmaceutical value chain could be found.
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Figure 4.3: The proposed methodology in Paper B to assess the value of pharma-
ceutical products from a full sustainability perspective.
The methodology proposed in Paper B suggests an approach by which to assess the
value of pharmaceutical products by integrating a full sustainability perspective, including
the social, economic and ecological sustainability dimensions, as value assessment crite-
ria. The assessment is performed by studying the consequences for the pharmaceutical
value chain of changing product design.
4.3.1 Proposed methodology
Figure 4.3 presents the proposed methodology of Paper B. The product platform approach
of Paper A is adapted to generate customizable product designs. A sustainability lifecycle
assessment, using SLCA2.0 [Villamil et al. 2018], is performed on customizable product
design, but also on a traditional product design to generate reference data. A qualitative
comparison with respect to sustainability criteria is performed between the customizable
and the traditional product design. The qualitative comparison is elaborated by studying
the pharmaceutical value chain and phases of the value chain prone to change due to a
change in product design. Variables in each value chain phase changing value-wise due
to a customizable product design are identified, quantified and categorized according to
the sustainability dimension affected from the value change. A model of value simula-
tions was established, where sustainability dimensions are acquiring weight, and hence,
can be used to give information regarding the sustainability dimension promoted by the
respective product design.
4.3.2 Illustrative case study
To illustrate the application of the methodology, a commercial treatment for hypertension
is adopted to serve as a foundation for developing the product platform for the customiz-
able product design. The traditional product embraces a fully integral tablet design. The
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Table 4.1: Scenarios for value modelling as performed in paper B.
Scenario 1 2 3 4 5 6
wsocial 0.67 0.67 0 0.33 0.33 0
wecological 0.33 0 0.67 0.67 0 0.33
weconomic 0 0.33 0.33 0 0.67 0.67
Figure 4.4: The value simulation results in Paper B of each scenario prepared in
Table 4.1.
customized product design embraces a modularized tablet design. This commercial treat-
ment also contributes reference data of traditional product design, when performing the
sustainability lifecycle assessment. The results of value simulations are presented in Fig-
ure 4.4. The value increase or decrease of the customizable product design compared to
the traditional product design is displayed. The scenarios simulated emphasize respective
sustainability dimension differently, hence weights are assigned to each sustainability di-
mension according to Table 4.1.
Conclusively, Paper B has suggested an approach by which to assess the value of
pharmaceutical product designs from a full sustainability perspective and by evaluating
the consequences of product designs on the pharmaceutical value chain. The results in
Figure 4.4 indicate that customizable product design is the preferred choice of product
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design if value is to be created from a social and ecological dimension. Furthermore, the
scenario emphasizing the social dimension the most and thereafter the economic dimen-
sion, still indicates that customized product design is the preferred product design choice.
4.4 Paper C: Integrated Product and Production
System Platforms in a Set-Based Manner En-
abling Personalized Medicines
The purpose of Paper C was to explore the adaptability of SBCE principles to develop
product and production system platforms for pharmaceutical products. The study was ini-
tiated by the perceived gap of lacking SBCE approaches to product and production system
design of customized pharmaceutical products. Since an initial proposal of an approach
to concurrent engineering of pharmaceutical products was made in Paper A, this study
builds on it. A further elaborated methodology to concurrently develop product and pro-
duction system platforms, with a more detailed approach to production systems modelling
compared to Paper A, is proposed. Further, an approach to extend the established inte-
grated product and production system platform, when the functional bandwidth of these
platforms are judged insufficient, is proposed. This approach to platform extension allows
the platform to respond to changing customer needs. Furthermore, the applicability of the
methodology is tested in the context of modularized tablet designs to generate knowledge
regarding modularized tablet designs as enablers for personalized medicines.
4.4.1 Proposed methodology
The methodology consists of three major domains, the platform preparation-, platform
extension- and platform execution-domains. Each domain will be described in succeeding
sections.
Platform preparation-domain
Conducting the activities in the platform preparation-domain, see Figure 4.5, results in an
integrated product and production platform. Sets of patient attributes and sets of manufac-
turing equipment specifications are translated through logical reasoning and literature into
EF-M trees of the product and the manufacturing equipment, respectively, by applying the
EF-M tree modelling approach [Schachinger and Johannesson, 2000]. The EF-M tree is
complemented with component trees of the product and the manufacturing equipment and
hence, the product and manufacturing equipment architectures have been established.
The functional bandwidth of the unit operation which joins the product architecture
with the manufacturing equipment is controlled by the respective architecture. Likewise,
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Figure 4.5: The activities of the platform preparation-domain in Paper C.
the joint functional bandwidth of the unit operation controls the architectures. The mod-
elling of the functional bandwidth of the joining unit operation is performed by applying
the producibility model by [Landahl et al. 2017]. The joint functioning bandwidth is
modelled by identifying control parameters of respective architecture and by studying the
interaction of these control parameters. This joint product - production system architec-
ture is further developed into an integrated product and production system platform by
complementing it with product and manufacturing equipment design parameters. The
platform modelling is performed in the CCM software [Claesson, 2006].
Platform extension-domain
The activities in the platform extension-domain, see Figure 4.6 are accurate to execute
when the functional bandwidth of the integrated platform is judged insufficient and needs
an extension. Hence, extension activities create a platform variant.
An insufficient integrated platform is the result of either changing customer needs
or changing manufacturing resources. As the sets of patient attributes or manufacturing
equipment specifications are updated, an update is required of either platform to cover
the new functional bandwidth. An update of either platform further updates the joint
functional bandwidth of the unit operation joining the platforms, and this change further
propagates to the remaining platform. Hence, an updated integrated product and produc-
tion system platform variant with an adjusted bandwidth has been established.
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Figure 4.6: The activities of the platform extension-domain in Paper C.
Platform execution-domain
Figure 4.7 outlines the activities in the platform execution-domain which are performed to
study the performance of the integrated product and production system platform variants.
A Bill-of-material (BOM) defines the execution space of the integrated product and
production system platform variants by informing what is needed in terms of product
and production system variants. Execution of the integrated platform variants generates
feasible sets of product and production system variants for which the performance is cal-
culated. The performance indicator is chosen according to the information to be acquired
from platform variants.
4.4.2 Illustrative case study
The proposed methodology was applied to a commercial treatment of diabetes. An inte-
grated product and production system platform variant for the traditional product design
of the treatment, i.e. a fully integral tablet design, was established. Further, a modu-
larized tablet design of the same treatment was introduced and hence, another platform
variant was established. The consequence of design on the tablet compression process
was studied by platform execution. The tablet compression time was used as a perfor-
mance indicator. For tablet compression, a tablet punching tool consisting of a single tip
was used to compress tablets of the traditional product design and two types of tools were
used to compress tablets of the modularized product design, tool1 consisting of 8 tips and
tool2 consisting of 14 tips. Table 4.2 summarizes the increase in tablet compression time
when introducing a modularized tablet design.
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Figure 4.7: The activities of the platform execution-domain in Paper C.
Table 4.2: Increase in tablet compression time in Paper C.
Case tTool1 tTool2
Traditional product design - -
Modularized product design 95% 1%
51
Conclusively, Paper C has successfully presented the first approach to set-based con-
current engineering of product and production system designs of pharmaceutical products.
Furthermore, the results show that a modularized tablet design increases the tablet com-
pression time; however, a multiple tip tool consisting of 16 tips achieves break-even in
tablet compression time for the modularized tablet design and the traditional tablet de-
sign. This result illustrates the application of the methodology to inform design decisions
regarding product or production system design (here, the tablet punch design) to achieve
the desired performance (here, measured as the tablet compression time).
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CHAPTER 5
Discussion
This chapter answers the research questions proposed in Chapter 1, as well as discussing
the quality of research results. Furthermore, the main scientific and industrial contribution
of the thesis is discussed.
5.1 Answering the research questions
The research questions posed in Chapter 1 will be answered in this section.
RQ1: How can pharmaceutical product designs be established to support product
customization and the consequences of these designs for the production assessed?
RQ1 is primarily addressed in Paper A and Paper C. By applying the CC method
[Claesson, 2006] to functional modelling, architectures of pharmaceutical products sup-
porting flexible product designs can be established. Thus, designs that support product
customization. To assess the consequences of flexible pharmaceutical product designs
for production the complexity factor by [Pugh, 1990] can be used. Further, an integrated
approach to product and production system modelling by applying the EF-M tree mod-
eling [Schachinger and Johannesson, 2000] to describe the architectures of the product
and production system, respectively, allows establishing customized product designs an
assessing the consequences for production. The integration of respective architecture re-
quires the produciblity model by [Landahl et al. 2017] to model the interaction between
the product and production system in joining unit operations.
The CC method [Claesson, 2006] is an approach to functional modelling, i.e. express-
ing the product according to its functions. Functional modelling as an approach to estab-
lish pharmaceutical product architectures was judged beneficial, since the focus could be
re-directed from a fixed solution space and physical realizations of product to rather con-
sider the functions that the product should embed. Later, when considering alternative
solutions to the functions, the design space is kept open and hence, allows assessing sets
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of solution alternatives. Further, these product architectures were developed into prod-
uct platform variants by complementing the architecture with product design parameters.
The CCM software [Claesson, 2006], which is based on the CC method [Claesson, 2006],
is a platform modelling software and was used to develop the product platform variants
of pharmaceutical products. Further, CCM allows execution of the platform generating
product variant sets, product families, grounded in the developed platforms. Hence, estab-
lishing product designs by employing the CC method [Claesson, 2006], support product
customization.
To assess the consequences of customized pharmaceutical product designs for pro-
duction, the complexity factor was adopted in Paper A. The complexity factor was used
as a proxy to provide the indication of production consequences. The complexity factor
is a measurement of product complexity, and hence, can provide indicate increasing pro-
duction complexity. More complex product designs might pressurize production systems,
for example in the sense of additional functionalities embedded in a product might re-
quire new production equipment to be installed to provide for this product function. The
complexity factor was thus used to indicate additional costs that might arise due to more
complex product designs. However, the complexity factor describes the complexity of the
product, but does not describe the real consequences for the production system. Hence,
more elaborate approaches to assess the consequences for production shall be studied.
Thus, the study of Paper C was conducted to provide a remedy for this desire of elaborate
modelling approach to production system consequence assessment.
Paper C adds an element of an approach to establish the architecture of the manu-
facturing equipment in parallel to establishing the architecture of the product. The EF-M
tree modelling by [Schachinger and Johannesson, 2000] was applied as an architecting
approach, which the CC method [Claesson, 2006] is built on. Further, the producibil-
ity model by [Landahl et al. 2017] is proposed to be used to model the joining of the
product and manufacturing equipment architectures. The producibility model studies the
interaction of the product and manufacturing equipment in the production unit operation
that is aiming at transforming the product into the desired state by using the manufac-
turing equipment. In the unit operation, a joined functioning bandwidth of the product
and manufacturing equipment is defined and hence, these entities are joined. The re-
sult is a combined product and production system architecture. This joined product and
production system architecture is further developed into an integrated product and produc-
tion system platform by complementing the architecture with product and manufacturing
equipment specific design parameters. The modelling of the integrated platform is per-
formed in CCM, similarly to Paper A. The execution of the integrated platform generates
sets of feasible product and production system platform variants and thus, information re-
garding various choices of product design and the feasible production system with which
to produce this product design can be acquired. Hence, the consequences for production
due to changes in product design can be assessed.
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RQ2: How can the value of pharmaceutical product designs supporting customiza-
tion be assessed?
RQ2 is mainly addressed in Paper B. By applying the CC method [Claesson, 2006]
to establish flexible product architectures, as described above, product designs support-
ing customization can be established. The SLCA2.0 method by [Villamil et al. 2018]
provided sustainability criteria according to which the value of customized pharmaceu-
tical product designs can be described from a full sustainability perspective. Studying
the consequences of product customization for the value chain, the set of value driving
criteria can be complemented. Finally, employing a concept screening matrix by [Ulrich
and Eppinger, 2012] the value of customized product designs can be value criteria-wise
compared to a reference concept and thus, the value of customized product design can be
assessed.
The methodology proposed in Paper B employs the SLCA2.0 method [Villamil et al.
2018] to perform sustainability assessment of pharmaceutical products. The SLCA2.0
method [Villamil et al. 2018] allows for a qualitative comparative sustainability assess-
ment of two product designs. The comparative sustainability assessment was used as a
basis to assess the consequences of a product design change for the pharmaceutical value
chain. Further, studies on the pharmaceutical value chain were performed, to complement
the information from SLCA2.0 with established literature. Benchmarking of variables of
the pharmaceutical value chain that are affected due to a change in product design was
conducted. These value chain impact variables were categorized according to sustainabil-
ity dimension affected, due to a change in product design. Finally, a concept screening
matrix [Ulrich and Eppinger, 2012] was adapted as a method by which assess the value of
the product designs. The identified impact variables of the value chain were used as value
criteria. The concept screening matrix was complemented with weightings on the value
chain impact variables with respect to the sustainability dimensions. Scenarios promot-
ing each of the sustainability dimension was created and hence, product design choices
guided by the preferred sustainability dimension was promoted. Hence, an approach by
which to assess the value of pharmaceutical product designs supporting customization
was proposed that incorporated a full sustainability perspective as value criteria.
RQ3: How can the product and production system be modeled so that the conse-
quences of changing customer needs can be assessed?
RQ3 is addressed in Paper C. The consequences of changing customer needs for the
production system can be modelled by an approach to dynamic integrated product and
production platform modelling. This dynamic modelling is performed by extending the
current integrated product and production system platform. Updating the product archi-
tecture and, consequently, the product platform according to updated customer needs pro-
vide a product platform responding to changing customer needs. The product platform
is updated by adjusting the product design parameters of product platform and the mod-
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elling of this update is performed in CCM. The updated product platform then causes a
change in the joint functioning bandwidth of the unit operation, that combines the product
and production system. The feasible joint functioning bandwidth in the unit operation is
updated in CCM. The updated joint functioning bandwidth of the unit operation might
require an adjustment in the functioning bandwidth of production system platform, and
hence is updated accordingly to the requirements set by the joint functioning bandwidth
of the unit operation. This updated functioning bandwidth ensures that the manufacturing
equipment, of the production system, providing for the unit operation, is able to produce
the updated product design according to changing needs. The update in the production
system platform is performed in CCM by updating the manufacturing equipment design
parameters. The process described provides for a new integrated platform variant. Execu-
tion of the integrated product and production platform model in CCM generates variants
of product and production system designs. Criteria, to indicate the performance of each
platform variant, shall be defined to assess the platform variants.
RQ4: How can modularized tablet designs enable personalized medicines?
RQ4 is addressed in Papers A, B and C. By introducing a few standardized modules of
various sizes as configurational means for tablets, substantial flexibility on a product level
can be achieved. By combining a few standardized modules in all possible combinations
the number of combinations increases rapidly and, consequently, the number of unique
product variants that can be established. Further, a modularized tablet design shows an
increase in value from a social and environmental sustainability perspective. The reason
for the increase in value is mainly due to the ability of modularized tablet designs to of-
fer flexible doses, and hence, the treatment dose can be adjusted according to the patient
need. Further, an accurate dose might relieve side effects, the release properties can be
adjusted due to modularized product design and the administration effort is judged to de-
crease. All these effects are believed to improve the efficiency and safety of the treatment.
From an environmental perspective, a modularized tablet design can promote a decrease
in raw material consumption and a decrease in end-of-life waste. Finally, even though the
tablet compression time of modularized tablet designs was longer than for the traditional
tablet design, the increase in time was not extensive. Additionally, it is believed that by
incorporating change-over times, an advantage from a modularized tablet design perspec-
tive can be achieved.
Simulations performed in Paper A showed the consequences from combinations of
different module sizes on the level of customization and manufacturing complexity. The
number of unique product variants, if only using a few module types to establish product
variants from, is rapidly increasing since the size and shape of the product has proven
to affect the release rate of the API. Thus, product variants with different release rates
can be configured by introducing various assembly sequences of a few different types of
modules. Further, adding a module consisting of solely filling material as configurational
means, with the purpose of giving a flexible size to the product, additional product vari-
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ants of unique sizes can be generated. The manufacturing complexity increased linearly
with an increasing level of customization. The translation of manufacturing complexity
to manufacturing cost shall be further studied to clarify the affordability of modularized
tablet designs.
From as social sustainability perspective, an increasing value of customizable product
design is mainly due to a flexible dose, and hence, the treatment dose can be adjusted
according to the patient need. Further, an accurate dose might relieve side effects, a mod-
ularized product design allows for adjustment of the release properties, using the same
reasoning as described above regarding product size and shape, and finally, the admin-
istration effort is judged to decrease due to the opportunity of adjusting the size and the
shape of the product variants. From an environmental perspective, a modularized product
design can promote a decrease in raw material consumption, which mainly is a conse-
quence from the accurate dosing offered to patients. Similarly, offering accurate dosing to
patients promotes the decrease of end-of-life waste, which might originate from both the
fact that a more accurate dosing is available and hence, any surplus substances leaving the
body ending up in the nature in vain is eliminated. Additionally, an increasing adherence
with a customized product design might decrease the waste generated.
5.2 Quality of research outcomes
This section will discuss the quality of research outcomes. The proposed methodologies
of Papers A, B and C and the outcomes of the illustrative case studies will be described.
The proposed methodologies are perceived as design theories in the context of pharmaceu-
tical products and hence, quality criteria proposed by [Buur, 1990] will be used to discuss
the research outcomes. Further, the proposed methodologies are perceived as simulation
models and thus, the quality criteria by [Sargent, 2013] will be used to discuss the re-
search outcomes. Finally, quality criteria defined by [Creswell, 2014] for qualitative and
quantitative studies as well as the specific criterion transferability proposed by [Alme-
felt, 2005] to assess outcomes of qualitative studies will be used to assess the quality of
research outcomes.
5.2.1 Proposed methodologies
The proposed methodologies of paper A, B and C will be assessed with respect to the
criteria validity and reliability.
Validity
The validity of the proposed methodologies of papers A, B and C are assessed with re-
spect to the criteria of conceptual model validation proposed by [Sargent, 2013] and the
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completeness criteria proposed by [Buur, 1990]. The core of these criteria is to assess if
the models or theories are sufficient for the question that these models or theories are set
to answer. As described by answering the RQs 1, 2 and 3 the proposed methodologies
were able to answer the research questions. Further, these methodologies were estab-
lished guided by these RQs and hence, are judged to be able to provide an answer to these
research questions sufficiently. The sufficiency is judged due to the prescriptive nature of
the research questions, i.e. the questions posed aims at answering the question of how de-
sign can be conducted in the context of personalized medicines. Proposals for approaches
of how design can be conducted in the context of personalized medicines are suggested.
Transferability, as suggested by [Almefelt, 2005] a criteria for valid research out-
comes of qualitative studies is evaluated for the methodologies proposed. The method-
ologies presented in paper A and C are transferable into other contexts and are performed
by simply adjusting the architecture established by the CC method [Claesson, 2006] or the
EF-M tree modelling approach [Schachinger and Johannesson, 2000] to the product and
the corresponding production system desired. The methodologies proposed are transfer-
able beyond pharmaceutical products since evidence to application of the approaches to
product and production system design have already been illustrated in other contexts, such
as in the context of aerospace products [Levandowski et al. 2014, Michaelis et al. 2015].
Further, product architecting and product complexity has been and should be co-discussed
since it is evident that the product architecture affects the complexity of the product. The
complexity factor by [Pugh, 1990] is a widely used concept and a suitable approach to
give an indication of product complexity, as long as discrete parts and product structural
complexity is considered. The methodology of Paper B is transferable into other con-
texts and is performed by adjusting the product platform generating customized products
according to the desired product, i.e. the same reasoning regarding transferability of prod-
uct architectures into other contexts applies here as described for Paper A above, since the
platform approach in paper B adopts the approach from paper A. Further, the SLCA2.0
method by [Villamil et al. 2018] is a general approach to life cycle assessment and hence,
is straightforward to be transferred into other contexts. The usage of SLCA2.0 has already
been demonstrated in the context of the aerospace industry by for example [Villamil et al.
2018]. Moreover, for the final value assessment, the modelling was performed by employ-
ing the concept screening matrix by [Ulrich and Eppinger, 2012]. The concept screening
matrix is an established and valid method to use when comparing concepts with each other
towards defined criteria. Overall the proposed methodology of Paper B is thus transfer-
able into contexts beyond the pharmaceutical industry.
Credibility, defined by [Sargent, 2013] as the confidence the user of a model has
in the model as well as the information retrieved, and the correlated concept verifica-
tion by acceptance by [Buur, 1990], is evaluated for the proposed methodologies. The
credibility of the theoretical elements of each methodology such as CC method [Claes-
son, 2006], E-FM tree modeling [Schachinger and Johannesson, 2000], complexity fac-
tor, SLCA2.0 [Villamil et al. 2018] and concept screening matrix [Ulrich and Eppinger,
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2012] can be judged to pose some level of credibility due to the widespread usage of these
methods in research and industrial applications [Levandowski et al. 2014,Michaelis et al.
2015, Villamil et al. 2018, Raudberget, 2015]. However, the criteria verification by ac-
ceptance as proposed by [Buur, 1990] cannot be fulfilled since these methodologies, i.e.
the synthesized methodologies from the collection of theoretical elements, have not been
applied or evaluated beyond the researchers conducting the study.
Reliability
The reproducibility criteria as described by [Creswell, 2014] and the correlated concept
consistency as described by [Buur, 1990] will be used to evaluate the proposed method-
ologies. An attempt to the fulfillment of these criteria has been performed by careful docu-
mentation of each step conducted while developing the proposed methodologies. Careful
documentation is an activity suggested by [Yin, 2009] to ensure the reliability of research
outcomes. Further, each chosen theoretical element to be synthesized into the proposed
methodologies has carefully been motivated, as well as the application of the methods has
been demonstrated. However, the choice regarding the theoretical elements used in the
methodologies are largely affected by the judgment of a suitable approaches made by the
researchers conducting the study, and also largely biased to the tradition of the research
group regarding the methods to work with. For example, the CC method [Claesson, 2006]
and the EF-M tree modeling approach [Schachinger and Johannesson, 2000] were cho-
sen as methods to describe the architectures of product and production systems which
are largely employed in the research group. However, a choice of a functional modeling
approach is motivated due to the ability of these approaches to keep the design solution
space wide but, another researcher might have chosen another approach.
5.2.2 Illustrative case studies
The applicability of the methodologies proposed are demonstrated through illustrative
case studies in the context of modularized tablet designs. The demonstrations of the appli-
cability of the methodologies have a two-fold purpose. The first purpose is to implement
the methodology into a computer and to perform simulations to study the behaviour of the
methodology, even perceived as a model. The second purpose of demonstrating the appli-
cability of the methodologies was to use these to generate knowledge about modularized
tablet designs.
Validity
The validity of the case selection should be discussed. Modularized tablet designs have
been discussed as enablers for personalized medicines [Bonhoeffer et al. 2018,Aleksovski
et al. 2015, Tissen et al. 2011, Yeleken et al. 2017], and hence, performing case studies
in this context is judged valid as several researchers in the field has seen the potential in
this type of product design.
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Resulting architectures, described by the EF-M tree modeling approach [Schachinger
and Johannesson, 2000] and CC method [Claesson, 2006] of the product can be used for
other pharmaceutical products. This is done by adjusting the functional requirements and
the design solutions to suit the product in question, however, the structural description
of the architecture is still general. This transferability has been analytically described in
paper B for insulin medication. No application in other pharmaceutical product context
has been demonstrated and shall be addressed in the future. Thus, the credibility of this
approach cannot be verified through acceptance by experienced designers, since this was
a first approach to apply these methodologies in the pharmaceutical product context. Sim-
ilarly, the SLCA2.0 method [Villamil et al. 2018] a first application in the pharmaceutical
product context and hence, need further verification to increase the credibility of using
this method in the pharmaceutical context.
Reliability
The criteria computerized model verification as described by [Sargent, 2013], i.e. the
procedure of ensuring correct implementation of the model into a computer is evaluated.
A correct implementation has been tried to achieve by describing the modeling and ex-
ecution procedure of throughout the research activities. However, the credibility of such
an implementation would increase with a third-party verification according to [Sargent,
2013]. A third-party verification has not been performed.
Applying the EF-M tree modeling [Schachinger and Johannesson, 2000] and CC
method [Claesson, 2006] as approaches to establish product and production system ar-
chitectures poses a difficulty of the reproducibility of the results. If the architecture of an
existing product or manufacturing equipment is modelled and the functions and means are
carefully defined, no difficulty of reproducing the results should exist. Even though, the
resulting EF-M tree might divert in between researchers the interfaces of the physically
realized components and modules should remain the same. However, to carefully define
the functions and means of a product or manufacturing equipment is in itself a difficulty
because, this activity is much depending on the researchers’ knowledge, experiences and
preferences. Further, if new functions are to be introduced to a product or alternative
means to solve the functions are considered, the reproducibility of the results appears
since, likewise, the modelling of the new functions and allocation of the functions into
means are much up to the researchers’ preferences, previous knowledge, available litera-
ture and so forth.
The sustainability assessment of pharmaceutical products performed by SLCA2.0
method [Villamil et al. 2018] was applied for the first time in the context of pharma-
ceutical products. The application of SLCA2.0 implies a sustainability analysis which is
guided by a set of questions to be answered for the product studied. Hence, the relevant
questions chosen from the pre-defined set of guiding questions to assess the sustainability
of pharmaceutical products, were judged by analyzing literature on sustainability studies
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of pharmaceutical products as well as by the previous knowledge of a group of experts
in the field of sustainable product development. Hence, the chosen guiding questions for
the sustainability assessment were purely based on researchers’ knowledge, experiences,
preferences and the literature studied and thus, another researchers ability of reproducing
the same results is uncertain. Conclusively, the reproducibility of the study becomes a
difficulty and hence, the reliability of the research outcome is threatened.
In Paper B the consequence analysis of customized product designs on the pharma-
ceutical value chain was performed by identifying variables prone to change due to a
change in product design. These variables originated from the sustainability assessment
conducted but also, from additional literature on pharmaceutical value chains and change
impact analysis performed when introducing new manufacturing technologies into the
value chain. Hence, deducing the value chain impact from this information was relying on
the logical thinking of the researchers conducting the study and hence, the reproducibility
of this activity is a clear difficulty for this study and further, threatens the reliability of the
research outcome.
Internal and external validity
In general, the case studies were mainly of a fictitious nature. The possibility of actually
producing such modules need to be further studied, to clarify the requirements of enabling
the production of such modules. Further, the ability of producing such modules need to be
empirically verified. In Paper C, the case was adopted from an empirical study by [Goh et
al. 2017] where the production of mini-tablets was demonstrated. However, the resulting
quality of the modules, a module dose inside the required tolerances, produced through
the studied tablet compression equipment was not discussed. Hence, the reliability of the
research outcomes need further validation.
The case study of Paper A, aiming at generating knowledge about the design of the
modules and the consequences of the module design on the level of customization and
the manufacturing complexity, required a sample of various API modules. These mod-
ules were different regarding the design of the modules, more specifically, the size of the
modules and the sample of the API modules was produced by the researchers conducting
the study. An internal validity threat is hence identified, that is the sampling of the case
data. The cases, the sample of modules, are defined with characteristics such as module
diameter, dose and so forth, that predispose the outcome of the experiments conducted
on this sample. The nature of the experiment was an exploration of the design space,
more specifically, explore the consequence of different sized modules on the level of cus-
tomization and manufacturing complexity. Further, the idea was to see the trends from
a decreasing module size or combinations of different sized modules with respect to the
level of customization and manufacturing complexity. Hence, the sample is considered
valid to be used for this purpose and hence, a threat to internal validity is judged to be
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eliminated in this case.
Likewise, sample selection can pose a threat to the internal validity of the research
outcomes of Paper B. A population was generated to represent a treatment need and, con-
sequently, represent the need of various product variants to be generated. For Paper B, the
population was assumed to be treated in a surplus manner, i.e. a patient of the population
was offered a treatment dose that was closest to the dose need of the patient, but a larger
dose than needed was offered (if a product variant embedding the dose of the patient did
not exist). Hence, the need of material to produce all the product variants of the population
might be overestimated when calculating the material consumption of production. This
overestimation becomes especially crucial for the material consumption when producing
the traditional product design, since only three product variants were produced and hence,
the majority of the population was assumed to receive a treatment of a higher dose than
needed. The customized product design was assumed to be produced at a more accurate
dose and hence, a surplus treatment is eliminated. Further studies should be conducted to
clarify how a population with a traditional product concept is treated to draw more accu-
rate conclusions.
Considering external validity threats, the generalization of the results beyond the ex-
perimental setting might pose a threat to validity of the research outcomes of Papers A,
B and C. Results regarding the benefits of modularized tablet designs from a level of
customization point of view, value perspective and production consequences might be
applicable to products beyond the pharmaceutical industry as long as modularized prod-
uct designs are considered. However, the findings regarding the benefits of modularized
product designs, i.e. the rapid increase in product variants by introducing a few standard-
ized modules for configurational means, draws upon the opportunity that the release rate
of the pharmaceutical product is depending on the size and the shape of the product. If
the consideration of release rate is applicable in other industries is evidently questionable.
However, findings indication toward an increased adherence and decreased administration
difficulty due to flexible size and shape of the product variants might be generalizable to
the food industry for example, where similar problems of food administration could be an
issue. Additional experiments in the desired context to enable a transfer of results would
hence need to be conducted if knowledge were to be generated from modularized product
designs in other contexts.
5.3 Thesis results contribution impact
As described in Chapter 1 this thesis should have relevance from both an academic re-
search and industrial point of view. Hence, this section will discuss the main scientific
and industrial contribution, respectively.
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5.3.1 Main scientific contribution
Known theories widely used in the manufacturing industry such as SBCE and platform-
based design has been demonstrated in a new context, the pharmaceutical product con-
text. This shows the transferability of these theories and further, that these are applicable
and effective in a wider context. To the pharmaceutical context, new evidence of the
benefits of modularized tablet designs has been provided as enablers for personalized
medicines. It has been shown that a vast increase in a number of product variants can be
obtained from a few standardized components and hence, can support a shift towards a
mass customization-paradigm of pharmaceutical products.
5.3.2 Main industrial contribution
A contribution has been made to the product development process of pharmaceutical prod-
ucts, showing upon approaches to integrated product and production system design. The
methodologies proposed contributes to the support for efficient product and production
system development of pharmaceutical products. This support can be applied in the
context of developing personalized medicines but also, in the current mass production-
paradigm. Further, an approach to integrate a full sustainability perspective to assess
pharmaceutical product designs contributes to the need for developing sustainable prod-
ucts. The increased knowledge of modularized tablet designs as enablers for personalized
medicines suggests approaches to product customization that can individualize therapy
and increase value and hence, perhaps the business of the pharmaceutical industry.
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CHAPTER 6
Conclusions
Conclusions of the thesis are described by analyzing the fulfilment of the thesis goals
posed in Chapter 1. Finally, suggestions for future research are proposed.
6.1 Conclusions
This thesis successfully proposes approaches to integrated product and production sys-
tem design in the context of pharmaceutical product customization. This is conducted
by proposing methodologies with which to establish integrated product and production
system designs of pharmaceutical products. Further, these methodologies adapt platform-
based design to product and production system design of pharmaceutical products. The
adaption of platform-based design is performed to support a mass customization-paradigm
of pharmaceutical products.
Paper A suggests an approach to establish product platforms for pharmaceutical prod-
ucts to ensure flexible product designs that support customization. The CC method [Claes-
son, 2006] is applied to establish flexible product designs. Further, Paper A suggests an
initial approach to integrate production considerations of flexible product designs by em-
ploying the complexity factor by [Pugh, 1990]. Paper B illustrates an integrated approach
to assess the value of customized pharmaceutical product designs by integrating a full
sustainability perspective as value indicator. A sustainability assessment is performed
by employing the SLCA2.0 method [Villamil et al. 2018] to assess the sustainability
of customized pharmaceutical product designs. Further, a consequence analysis of cus-
tomized products for the pharmaceutical value chain is demonstrated. Paper C suggests
an approach to integrated product and production system design by establishing product
and production system architectures, employing the EF-M tree model [Schachinger and
Johannesson, 2000]. The EF-M tree modelling approach supports the development of
flexible product designs that support customization. Further, an approach to join these ar-
chitectures is proposed by applying the producibility model by [Landahl et al. 2017]. This
joint architecture is developed into an integrated product and production system platform
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to enable the consequence assessment of product design for production system design.
This thesis demonstrates an adaption of SBCE principles in the context of pharmaceu-
tical products successfully. The adaption of SBCE is illustrated in Paper A by suggesting
an approach to generate product families, applying the CC method [Claesson, 2006], and
assessing the performance of these product families by adopting the complexity factor
by [Pugh, 1990]. The adaption of SBCE principles in Paper C is illustrated by a dynamic
modelling approach of integrated product and production platforms, applying the EF-
M tree modelling approach [Schachinger and Johannesson, 2000] and the producibility
model [Landahl et al. 2017]. The update of the established integrated product and pro-
duction system platform to enable response to changing customer needs is demonstrated,
hence generating sets of product and production system platform variants. Paper C further
suggests an approach to assess the performance of these variants by choosing criteria to
indicate the success of a variant.
This thesis has contributed to the following knowledge regarding modularized tablet
designs as enablers for personalized medicines:
• By introducing a few standardized modules of different sizes, for configurational
means of a product, substantial flexibility on a product level can be achieved.
• A modularized tablet design can increase product value from a social and environ-
mental sustainability perspective.
• A modularized tablet design can be an affordable design to support pharmaceutical
product customization.
6.2 Future work
Thus far, research has assumed an exploratory nature. Various methodologies have been
proposed to suggest approaches to an efficient pharmaceutical product and production
development process of products supporting a mass customization-paradigm. This has
been performed by proposing engineering-based approaches and methods to concurrently
develop product and production system platforms for pharmaceutical products. These
methodologies build on assumptions that working concepts applied in the manufacturing
industry, such as platform-based development and SBCE principles, will work in the phar-
maceutical context and are hence worth exploring. Further studies should be conducted
to look into what type of information these methodologies should generate in order to be
valid tools to implement into an industrial context.
Thus far, work has been focusing on setting up system-level models to integrated
product and production system platforms. These platforms have been employed by study-
ing the consequences of changing pharmaceutical product design from a traditional fully
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integral to modularized product design. The production system of these product design
has been assumed to reside in the current mass production paradigm. In the future, stud-
ies focusing on production systems shall be conducted to explore the existing opportuni-
ties of current production systems in industries beyond the pharmaceutical. Additionally,
production systems for pharmaceutical products supporting mass customization will be
studied to clarify the requirements on these in order to enable mass customization.
The system-level simulations regarding the modularized tablet designs have thus far
mainly been considering dose and size flexibility as design parameters for customized
product designs. The release rate of the drug substance is an important parameter to
consider for customization. Models regarding release customization are essential to be
incorporated to enable predictive modelling of product design. Hence, the release rate of
drugs will be considered in future work.
The illustrative case studies have focused on oral dosage forms, more specifically
tablets. Future studies should consider other pharmaceutical products to ensure the appli-
cability of the methodologies beyond the oral dosage forms. Additionally, the illustrative
case studies were mainly of a fictitious nature and thus, empirical information for es-
tablishing such modularized product designs need to be gathered to further develop the
models and enable better predictive simulations of product and production system design.
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